Professor John Snowden

BSc, MBChB, MD, FRCP (London), FRCP (Edin), FRCPath, DTM&H

Clinical Medicine, School of Medicine and Population Health

Honorary Professor

Consultant Haematologist

Director of Blood and Marrow Transplantation (BMT) Programme, Sheffield Teaching Hospitals NHS Foundation Trust.

john.snowden1@nhs.net
+44 114 271 3357

Royal Hallamshire Hospital

Full contact details

Professor John Snowden
Clinical Medicine, School of Medicine and Population Health
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF

Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I trained as an undergraduate in the University of Leeds, and as a postgraduate in the UK, Australia and New Zealand. I have been Consultant Haematologist and Director of the Blood and Marrow Transplantation & Cellular Therapy Programme in Sheffield Teaching Hospitals NHS Foundation Trust, UK since 2002. I have recently been the Co-Lead Clinician for Haemato-Oncology of the North East & Yorkshire region Genomic Laboratory Hub (GLH), 2019-25. I am due to take up the post of Professor of Haematology at The University of Sheffield in February 2025.

Nationally, I have held several key leadership roles in Blood and Marrow Transplantation (BMT) and Haemato-oncology, including Clinical Lead for various NICE Guidelines and Chair of the NHS England Clinical Reference Group for BMT (2016-20). From 2017-20, I was Chair of the Intercollegiate Committee on Haematology (ICH) to the Royal College of Physicians and Royal College of Pathologists. I was President of the British Society of Blood and Marrow Transplantation & Cellular Therapy (BSBMTCT) for 2021-22 and continued within the Board of Trustees as Past President (2023-24). In 2022, I was elected to the Board of Trustees of the British Society for Haematology (BSH).

Internationally, I have a long association with the European Society for Blood and Marrow Transplantation (EBMT) and the international accreditation organisation for transplant programmes, ‘JACIE’, including JACIE Medical Director (2012-16) and Chair of the JACIE Committee (2015-20). I have served as a member of the EBMT Board and Scientific Council initially as Autoimmune Diseases Working Party Chair (2016-20) and as Secretary to EBMT from 2020-24.

Academically, I have contributed to the fields of BMT, haematology-oncology and autoimmunity with authorship of over 400 publications (Google Scholar h-index 74, with over 20,000 citations), along with clinical trials, grant awards, educational meetings, teaching, supervision, examination, journal editorship and scientific peer review. I have been awarded honorary professorships by The University of Sheffield and University College London (UCL).

Current/recent appointments

Consultant Haematologist & Director of Blood and Marrow Transplantation (BMT) Programme, Sheffield Teaching Hospitals NHS Foundation Trust, 2002-25.
Honorary Professor, Division of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, UK, 2013-25.
Honorary Clinical Professor, Department of Haematology, The Cancer Institute, UCL, 2016-25.
Secretary to the European Society for Blood and Marrow Transplantation (EBMT), 2020-24.
President of British Society of Blood and Marrow Transplantation & Cellular Therapy (BSBMTCT), 2021-22.
Chair of the Intercollegiate Committee on Haematology (ICH) to the RCP (London) and RCPath, 2017-20.
Co-Lead Clinician for Haematology-Oncology in the NHS England Genomic Laboratory Hub (GLH) for North-East & Yorkshire (NEY) region, 2019-25.
British Society for Haematology (BSH), Elected Member of Board of Trustees, 2022-25.

Qualifications

BSc Pathology, First Class Honours, University of Leeds, 1987.
- Willis Prize in Pathology, University of Leeds 1987.
MBChB Medicine, University of Leeds, 1989.
- Paul Fitton Prize in Anaesthesia, Association of Anaesthetists, UK 1988.
- Pullen Prize in Obstetrics and Gynaecology, University of Leeds 1989.
- William MacAdam Prize in Medicine, University of Leeds 1989.
Membership of the Royal College of Physicians, MRCP (UK), 1992.
Membership of the Royal College of Pathologists, MRCPath, 1999.
Doctor of Medicine, MD, University of Leeds, 1999.
Specialist Certification in Haematology, 1999.
Fellowship of the Royal College of Physicians of London, FRCP (Lond), 2004.
Fellowship of the Royal College of Pathologists, FRCPath, 2007.
Fellowship of the Royal College of Physicians of Edinburgh, FRCP (Edin), 2019.
Diploma in Tropical Medicine & Hygiene, DTM&H, awarded by RCP London 2021.

Research interests

In conjunction with NHS roles, my principal academic areas of interest are:

Blood and marrow stem cell transplantation in cancer and non-malignant disorders.
Physical and psychological late effects in survivors of cancer treatment and BMT.
Multiple myeloma, from cell biology to supportive care and survivorship research.
Leukaemia and other haematological cancers.
Service development, ‘quality’, accreditation, benchmarking and health economics in haemato-oncology and BMT.

My academic activity is reflected by:

Full publication of over 400 medical & scientific articles, with Google Scholar citation h-index of 74 and over 20,000 total citations.
Over £10 million in grant awards as co-applicant or chief/principal investigator.
Organising numerous national and international conferences.
Regular invitations to speak and chair sessions at numerous national & international meetings.
Extensive scientific peer review for respected general and specialist journals.
Collaborations with other national and international Haemato-oncology and BMT Programmes.
Principal Investigator/Chief Investigator roles in multicentre National Institute for Health Research (NIHR), National Cancer Research Institute (NCRI), investigator-led and industry sponsored clinical research trials.
Delivering undergraduate/postgraduate teaching, supervision, training, examination in Sheffield Teaching Hospitals, The University of Sheffield and Sheffield Hallam University.
External examiner for PhD examinations in other Universities (Birmingham, Newcastle, Oxford).

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Mayor NP, Szydlo RM, Sheikh Y, Lee J, Pearce RM, Farrow C, Agapiou M, Rao K, Orchard K, Olavarria E , Marsh SGE et al (2024) The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience. The Lancet Haematology, 11(12), E916-E926. View this article in WRRO
Lindsay JO, Hind D, Swaby E, Berntsson H, Bradburn M, Bannur U, Byrne J, Clarke C, Desoysa L, Dickins B , Din S et al (2024) Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn’s disease (ASTIClite): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology and Hepatology. View this article in WRRO
Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M , Pirrie S et al (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29(7), 1760-1774. View this article in WRRO
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C , Ciceri F et al (2023) Immune effector cell-associated hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations. Blood Journal. View this article in WRRO
Saccardi R, Putter H, Eikema D-J, Busto MP, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FA, Baldomero H , Beguin Y et al (2023) Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation.
Clark A, Thomas S, Hamblin A, Talley P, Kulasekararaj A, Grinfeld J, Speight B, Snape K, McVeigh TP & Snowden JA (2023) Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). British Journal of Haematology.
Snowden JA, Ahmedzai SH, Cox A, Cairns DA, Ashcroft AJ, Williams C, Cavenagh JD, Hockaday A, Brown JM, Brock IW , Morris TCM et al (2022) Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation, 57(10), 1507-1513.
Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R , Lankester AC et al (2022) Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.. Bone Marrow Transplantation. View this article in WRRO
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R , Sanchez-Guijo F et al (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology, 33(3), 259-275.
Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D , Poirel HA et al (2020) Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 55(4), 681-694.
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA , Carlson K et al (2019) Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 321(2), 165-174. View this article in WRRO
Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, Kuball J, Chabannon C & Mohty M (2017) JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement.. Bone Marrow Transplant. View this article in WRRO
Snowden JA, Greenfield DM, Bird JM, Boland E, Bowcock S, Fisher A, Low E, Morris M & Pratt G (2017) Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. British Journal of Haematology, 176(6), 888-907. View this article in WRRO
Sharrack B, Petrie J, Coles A & Snowden JA () Is stem cell transplantation safe and effective in multiple sclerosis?. BMJ, e061514-e061514.
Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K , Labopin M et al () Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases : updated guidelines and recommendations from the EBMT autoimmune diseases working party (ADWP) and the joint accreditation committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation. View this article in WRRO

All publications

Books

Burt RK, Farge D, Ruiz MA, Saccardi R & Snowden JA () Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases. CRC Press.

Journal articles

Mayor NP, Szydlo RM, Sheikh Y, Lee J, Pearce RM, Farrow C, Agapiou M, Rao K, Orchard K, Olavarria E , Marsh SGE et al (2024) The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience. The Lancet Haematology, 11(12), E916-E926. View this article in WRRO
Hamad N, Takamatsu H, Gras L, Koster L, Baaij L, D'Souza A, Estrada-Merly N, Hari PN, Cowan AJ, Saber W , Iida M et al (2024) Race and Ethnicity As a Category Poses Challenges in Global Registries: Experience from the Waustim Project of the Worldwide Network for Blood and Marrow Transplantation, WBMT. Blood, 144(Supplement 1), 7848-7848.
Cowan AJ, Gras L, Takamatsu H, Koster L, Baaij L, Hamad N, D'Souza A, Estrada-Merly N, Hari PN, Saber W , Iida M et al (2024) Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study. Blood, 144(Supplement 1), 2379-2379.
Beksac M, Iacobelli S, Gras L, Koster L, Baaij L, Hamad N, D'Souza A, Estrada-Merly N, Hari PN, Cowan AJ , Saber W et al (2024) Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study. Blood, 144(Supplement 1), 4733-4733.
Cook G, Ashcroft AJ, Senior E, Olivier C, Hockaday A, Richards J, Cavenagh JD, Snowden JA, Drayson MT, de Tute R , Roberts L et al (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, S2352-3026(24)00249.
Parrish C, Welsh A, Ashcroft J, Olivier C, Hockaday A, Cavenagh J, Snowden J, Drayson M, De Tute R, Owen R , Yong K et al (2024) OA-59 Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 24, S37-S38.
Brittain G, Roldan E, Alexander T, Saccardi R, Snowden JA, Sharrack B & Greco R (2024) The Role of chimeric antigen receptor T‐cell therapy in immune‐mediated neurological diseases. Annals of Neurology. View this article in WRRO
Baldomero H, Neumann D, Hamad N, Atsuta Y, Sureda A, Iida M, Karduss A, Elhaddad AM, Bazuaye NG, Bonfim C , Camara RDL et al (2024) The Role of Registries in Hematological Disorders. Best Practice & Research Clinical Haematology, 101556-101556.
Patel B, Kirkwood AA, Rowntree CJ, Alapi KZ, Barretta E, Clifton‐Hadley L, Creasey T, Lee S, Marks DI, Moorman AV , Morley N et al (2024) Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia. HemaSphere, 8(6).
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L , Richter A et al (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Rheumatology, 6(6), e339-e351.
Alexander T, Tassy N, Domenech A, Kramer E, Jessop H, Kenyon M, Sharrack B, Saccardi R, Bolanos N, Snowden JA & Greco R (2024) Patient-reported-outcomes in HSCT for autoimmune diseases: considerations on behalf of the EBMT ADWP, PAC and Nurses Group. Journal of Allergy and Clinical Immunology: Global, 100283-100283.
Brittain G, Cooper C, Glover R, Loban A, Muraro P, Papaioannou D, Roldan E, Sharrack B & Snowden J (2024) Aggressive Multiple Sclerosis: Clinical Phenotype and Treatment Within a Randomised Clinical Trial of Autologous Haematopoietic Stem Cell Transplantation vs High Efficacy Disease Modifying Treatment (P9-6.004). Neurology, 102(17_supplement_1).
Passweg JR, Baldomero H, Ciceri F, de la Cámara R, Glass B, Greco R, Hazenberg MD, Kalwak K, McLornan DP, Neven B , Perić Z et al (2024) Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation.
Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, Byrne J, Clarke C, Desoysa L, Din S , Emsley R et al (2024) Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCT. Efficacy and Mechanism Evaluation, 11(3). View this article in WRRO
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K , Onida F et al (2024) Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine, 69, 102476-102476.
Lindsay JO, Hind D, Swaby E, Berntsson H, Bradburn M, Bannur U, Byrne J, Clarke C, Desoysa L, Dickins B , Din S et al (2024) Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn’s disease (ASTIClite): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology and Hepatology. View this article in WRRO
Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, Roldan E, Beecher C, Bursnall M, Ciccarelli O , Coles AJ et al (2024) Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ Open, 14(2), e083582-e083582.
Sanchez-Guijo F, Vives J, Ruggeri A, Chabannon C, Corbacioglu S, Dolstra H, Farge D, Gagelmann N, Horgan C, Kuball J , Neven B et al (2024) Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT). Cytotherapy.
Kulasekararaj A, Cavenagh J, Dokal I, Foukaneli T, Gandhi S, Garg M, Griffin M, Hillmen P, Ireland R, Killick S , Mansour S et al (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. British Journal of Haematology.
Hughes SL, Prettyjohns MJ, Snowden JA & Sharrack B (2024) Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases, 279-294.
Kirgizov K, Burman J, Snowden JA & Greco R (2024) Autologous hematopoietic stem cell transplantation for pediatric autoimmune neurologic disorders, 249-258.
Robin M, Iacobelli S, Passweg JR, Koster L, Potter V, Wilson K, Salmenniemi U, Dreger D, von dem Borne P, Snowden J , Robinson S et al (2023) Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT. Blood, 142(Supplement 1), 473-473.
Garderet L, Gras L, Koster L, Rovira M, Vincent L, Kobbe G, Pillai S, Deeren D, Kaufmann M, Kuball J , Ozdogu H et al (2023) Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT. Blood, 142(Supplement 1), 3403-3403.
Cook G, Ashcroft AJ, Senior ER, Olivier C, Hockaday A, Richards J, Cavenagh JD, Snowden J, Drayson M, de Tute RM , Owen R et al (2023) Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD). Blood, 142(Supplement 1), 783-783.
Mizuno S, Gras L, Baaij L, Koster L, D'Souza A, Hari PN, Estrada-Merly N, Saber W, Cowan AJ, Iida M , Okamoto S et al (2023) Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study. Blood, 142(Supplement 1), 785-785.
Gurnari C, Koster L, Baaij L, Heiblig M, Yakoub-Agha I, Passweg JR, Clay J, Kuball J, Rambaldi A, Hayden PJ , Badoglio M et al (2023) Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT. Blood, 142(Supplement 1), 708-708.
Murray SM, Pose E, Wittner M, Londoño M-C, Schaub G, Cook J, Dimitriadis S, Meacham G, Irwin S, Lim Z , Duengelhoef P et al (2023) Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients. Journal of Hepatology.
Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M , Pirrie S et al (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29(7), 1760-1774. View this article in WRRO
Beksac M, Iacobelli S, Koster L, Cornelissen J, Griskevicius L, Rabin NK, Stoppa AM, Meijer E, Mear J-B, Zeerleder S , Mayer J et al (2023) Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT.. Bone Marrow Transplant.
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C , Ciceri F et al (2023) Immune effector cell-associated hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations. Blood Journal. View this article in WRRO
Birck MG, Alexander T, Labopin M, Greco R, Badoglio M, Snowden J, Sureda Balari A, Uuema A, Van Biezen A, Lavoie JR , Gao J et al (2023) POS1248 OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL AND RELAPSE RATES ARE SIMILAR IN FEMALES VERSUS MALES UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases, 82(Suppl 1), 964.2-965.
Pagliuca S, Kulasekararaj AG, Eikema D-J, Piepenbroek B, Iftikhar R, Satti TM, Griffin M, Laurino M, Kupesiz A, Bertrand Y , Fattizzo B et al (2023) Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society of Blood and Marrow Transplantation. Haematologica.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R , Grigg A et al (2023) Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurology, 80(7), 702-713. View this article in WRRO
Greco R, Snowden JA, Knelange NS, Tridello G, Cacciatore C, Xhaard A, Ciceri F, Collin M, Ferra C, De Becker A , Averbuch D et al (2023) Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases. Journal of Autoimmunity, 136.
Yakoub-Agha I, Greco R, Onida F, de la Cámara R, Ciceri F, Corbacioglu S, Dolstra H, Glass B, Kenyon M, McLornan DP , Neven B et al (2023) Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplantation.
Devillier R, Eikema D-J, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J , Renard C et al (2023) Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT.. Haematologica.
Bruno A, Gurnari C, Alexander T, Snowden JA & Greco R (2023) Autoimmune manifestations in VEXAS: opportunities for integration and pitfalls to interpretation. Journal of Allergy and Clinical Immunology.
Tridente A, Dempsey NC, Khalifa M, Goddard J, Shuker K, Hall J, Sorour Y, Wright J, Webber S, Mills GH & Snowden JA (2023) Predicting outcomes of hematological malignancy patients admitted to critical care. Frontiers in Hematology, 2.
Saccardi R, Putter H, Eikema D-J, Busto MP, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FA, Baldomero H , Beguin Y et al (2023) Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation.
Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, McLornan DP, Neven B , de Latour RP et al (2023) Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT activity survey. Bone Marrow Transplantation.
Clark A, Thomas S, Hamblin A, Talley P, Kulasekararaj A, Grinfeld J, Speight B, Snape K, McVeigh TP & Snowden JA (2023) Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). British Journal of Haematology.
Waszczuk-Gajda A, Gras L, de Wreede LC, Sirait T, Illes A, Ozkurt ZN, Snowden JA, Arat M, Bulabois CE, Niederland J , Sever M et al (2023) Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—the DIADEM study from the chronic malignancies working party of the EBMT. Bone Marrow Transplantation.
Miller PDE, Patel SR, Skinner R, Dignan F, Richter A, Jeffery K, Khan A, Heath PT, Clark A, Orchard K , Snowden JA et al (2023) Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children's cancer and Leukaemia Group (CCLG), and British Infection Association (BIA). Journal of Infection, 86(1), 1-8.
Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBC, Kröger N, Mohty M, Galeano S, Okamoto S , Chaudhri N et al (2022) An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplantation and Cellular Therapy.
Hayden PJ, Eikema D-J, Koster L, Snowden JA, Caillot D, Van Gorkom G, Griskevicius L, Arcese W, Crawley C, Musso M , Bulabois C-E et al (2022) Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021. Blood, 140(Supplement 1), 10434-10436.
Duque Afonso J, Finke J, Ngoya M, Galimard J-E, Craddock C, Raj K, Bloor A, Nicholson E, Eder M, Orchard KH , Valerius T et al (2022) Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party. Blood, 140(Supplement 1), 2110-2112.
Patel Wrench B, Kirkwood AA, Alapi KZ, Clifton-Hadley L, Lee S, Marks DI, Moorman AV, Morley NJ, Patrick P, Rana Z , Rowntree CJ et al (2022) Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia. Blood, 140(Supplement 1), 6125-6126.
Doglio M, Alexander T, Del Papa N, Snowden JA & Greco R (2022) New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies. Journal of Allergy and Clinical Immunology, 150(6), 1289-1301.
Lawless S, Iacobelli S, Knelange NS, Chevallier P, Blaise D, Milpied N, Foà R, Cornelissen JJ, Lioure B, Benjamin R , Poiré X et al (2022) Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling. Haematologica.
Jones GL, Moss RH, Darby F, Mahmoodi N, Phillips B, Hughes J, Vogt KS, Greenfield DM, Brauten-Smith G, Gath J , Campbell T et al (2022) Cancer, fertility and me: developing and testing a novel fertility preservation patient decision aid to support women at risk of losing their fertility because of cancer treatment. Frontiers in Oncology, 12.
Snowden JA, Ahmedzai SH, Cox A, Cairns DA, Ashcroft AJ, Williams C, Cavenagh JD, Hockaday A, Brown JM, Brock IW , Morris TCM et al (2022) Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation, 57(10), 1507-1513.
Wolf J, Lee J, Pearce R, Wilson M, Snowden JA & Orchard K (2022) The impact of COVID-19 on related-donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey.. Br J Haematol.
Sharrack B, Snowden J & Muraro P (2022) 019 Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (StarMS). Journal of Neurology Neurosurgery & Psychiatry, 93(6), a19.2-a1a19.
Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R , Lankester AC et al (2022) Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.. Bone Marrow Transplantation. View this article in WRRO
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U , Hilgendorf I et al (2022) Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.. Bone Marrow Transplant.
Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS , Prasad P et al (2022) Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.. Bone Marrow Transplant.
Cartwright A, Snowden JA, Whitehouse H, Scott S & Whitby L (2022) Implementation of the updated NICE haematological cancers (NG47) improving outcomes guidelines across Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) in England : a UK NEQAS LI survey. Journal of Clinical Pathology.
Achini‐Gutzwiller FR, Snowden JA, Corbacioglu S, Greco R, Greco R, Alexander T, Snowden J, Badoglio M, Labopin M, Abinun M , Apte S et al (2022) Haematopoietic stem cell transplantation for severe autoimmune diseases in children : a review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 198(1), 24-45.
Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, Mohty M, Neven B , Peffault de Latour R et al (2022) Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 57, 742-752. View this article in WRRO
Drozd-Sokołowska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G, Pouli A, Crawley C, Wilson KMO, Tilly H , Byrne J et al (2022) Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT. Bone Marrow Transplantation, 57(4), 633-640. View this article in WRRO
Montoto S, Snowden JA, Chabannon C, Corbacioglu S, de la Camara R, Dolstra H, Greco R, Gusi A, Hamad N, Kenyon M , Kröger N et al (2022) The first steps towards a diverse and inclusive EBMT: a position paper. Bone Marrow Transplantation, 57(3), 343-346.
Cencioni MT, Genchi A, Brittain G, de Silva TI, Sharrack B, Snowden JA, Alexander T, Greco R & Muraro PA (2022) Immune reconstitution following autologous hematopoietic stem cell transplantation for multiple sclerosis : a review on behalf of the EBMT autoimmune diseases working party. Frontiers in Immunology, 12. View this article in WRRO
Ros-Soto J, Snowden JA, Szydlo R, Nicholson E, Madrigal A, Easdale S, Potter M, Ethell M & Anthias C (2022) Outcomes following DLI in patients with haematological malignancies: Donor characteristics matter. Transplantation and Cellular Therapy.
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R , Sanchez-Guijo F et al (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology, 33(3), 259-275.
Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS , Prasad P et al (2022) Male-specific late effects in adult hematopoietic cell transplantation recipients : a systematic review from the late effects and quality of life working committee of the Center for International Blood and Marrow Transplant Research and transplant complications working party of the European Society of Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 28(6), 335.e1-335.e17.
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N , Hamidieh AA et al (2022) One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 107(5), 1045-1053. View this article in WRRO
Marzolini MAV, Mehra V, Thomson KJ, Tholouli E, Bloor AJC, Parker A, Lovell R, Orchard K, Publicover A, Nicholson E , Snowden JA et al (2021) Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting. Blood Advances, 5(21), 4500-4503. View this article in WRRO
Alexander T, Snowden JA, Burman J, Chang H-D, Del Papa N, Farge D, Lindsay JO, Malard F, Muraro PA, Nitti R , Salas A et al (2021) Intestinal microbiome in hematopoietic stem cell transplantation for autoimmune diseases : considerations and perspectives on behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. Frontiers in Oncology, 11.
Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P , Ganser A et al (2021) Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT.. Bone Marrow Transplant.
Snowden JA, McGrath E, Orchard K, Kröger N, Sureda A & Gratwohl A (2021) Visions for a JACIE quality management system 4.0. Bone Marrow Transplantation, 56(12), 2876-2881. View this article in WRRO
Peric Z, Peczynski C, Polge E, Kröger N, Sengeloev H, Radujkovic A, Helbig G, Russell N, Bunjes D, Socié G , Potter V et al (2021) Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. Bone Marrow Transplantation.
Petit AF, Kulasekararaj AG, Eikema D-J, Maschan A, Adjaoud D, Kulagin A, Grassi A, Fagioli F, Griskevicius L, Snowden JA , Johansson J-E et al (2021) Upfront unrelated donor Hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: a retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation.. Am J Hematol.
Mawson S, Keen C, Skilbeck J, Ross H, Smith L, Dixey J, Walters SJ, Simpson R, Greenfield DM & Snowden JA (2021) Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study. Physiotherapy, 113, 88-99. View this article in WRRO
Greco R, Alexander T, Burman J, Del Papa N, de Vries-Bouwstra J, Farge D, Henes J, Kazmi M, Kirgizov K, Muraro PA , Ricart E et al (2021) Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplantation, 56, 1493-1508.
Colton H, Greenfield DM, Snowden JA, Miller PDE, Morley NJ, Wright J, Darton TC, Evans CM & de Silva TI (2021) Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant. Vaccine, 39(34), 4778-4783.
Lwin SM, Snowden JA & Griffiths CEM (2021) The Promise and Challenges of Cell Therapy for Psoriasis.. Br J Dermatol.
Puyade M, Patel A, Lim YJ, Blank N, Badoglio M, Gualandi F, D. D, Maximova N, Greco R, Alexander T & Snowden JA (2021) Autologous hematopoietic stem cell transplantation for Behçet’s disease: a retrospective survey of patients treated in Europe, on behalf of the autoimmune diseases working party of the European Society for Blood and Marrow Transplantation. Frontiers in Immunology, 12. View this article in WRRO
Burt RK, Muraro PA, Farge D, Oliveira MC, Snowden JA, Saccardi R, Han X, Quigley K, Bueno V, Frasca D , Fedorenko D et al (2021) New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis.. Bone Marrow Transplant.
Greco R, Peccatori J, Bonifazi F, Snowden JA & Ciceri F (2021) Editorial: Novel immunological biomarkers for allogeneic HSCT outcome. Frontiers in Immunology, 12. View this article in WRRO
Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cámara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R , Lankester AC et al (2021) Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 56(7), 1651-1664.
Gratwohl A, Passweg J, Baldomero H, Orchard K, Kröger N, Snowden JA & Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy Europe (ISCT), the European Society for Blood, Marrow Transplantation (EBMT) (2021) Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit.. Br J Haematol.
Das J, Snowden JA, Burman J, Freedman MS, Atkins H, Bowman M, Burt RK, Saccardi R, Innocenti C, Mistry S , Laud PJ et al (2021) Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis. Multiple Sclerosis Journal.
Orchard K, Dignan FL, Lee J, Pearce R, Desai M, McFarlane E, Parkin A, Shearn P & Snowden JA (2021) The NICE COVID‐19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact. British Journal of Haematology, 192(3), 467-473.
Jackson GH, Pawlyn C, Cairns DA, de Tute RM, Hockaday A, Collett C, Jones JR, Kishore B, Garg M, Williams CD , Karunanithi K et al (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18(1).
Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Fearnside J, Coleman RE & Greenfield DM (2021) Correction to: Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer, 29(2), 1145-1145.
Alexander T, Greco R & Snowden JA (2021) Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Annual Review of Medicine, 72(1), 215-228.
Dignan FL, Hamblin A, Chong A, Lee J, Kenyon M, Miller P, Gilleece M, Hunter H & Snowden JA (2021) Survivorship care for allogeneic transplant patients in the UK NHS : changes centre practice, impact of health service policy and JACIE accreditation over 5 years. Bone Marrow Transplantation, 56(3), 673-678.
Roberts F, Hobbs H, Jessop H, Bozzolini C, Burman J, Greco R, Ismail A, Kazmi M, Kirgizov K, Mancardi G , Mawson S et al (2020) Rehabilitation before and after autologous haematopoietic stem cell transplantation (AHSCT) for patients with multiple sclerosis (MS): Consensus guidelines and recommendations for best clinical practice on behalf of the autoimmune diseases working party, nurses group, and patient advocacy committee of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Neurology, 11. View this article in WRRO
Puyade M, Patel A, Yeong LL, Blank N, Badoglio M, Gualandi F, Ma D, Maximova N, Grecco R, Alexander T & Snowden J (2020) Autogreffe de cellules souches dans la maladie de Behçet: analyse rétrospective du registre de l’European Society for Blood and Bone Marrow Transplantation. La Revue de Médecine Interne, 41, A72-A73.
Petit AF, Eikema D-J, Maschan A, Adjaoud D, Kulagin A, Rambaldi A, Fagioli F, Griškevičius L, Snowden JA, Johansson J-E , Dalle J-H et al (2020) Upfront Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Aplastic Anemia: A Study on Behalf of the Saawp of EBMT. Blood, 136(Supplement 1), 11-13.
Devillier R, Eikema D-J, Bosman P, Dufour C, Aljurf M, Wu D, Maschan A, Afanasyev BV, Halkes C, Collin MP , Snowden JA et al (2020) Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT. Blood, 136(Supplement 1), 3-4.
Scheid C, Eikema D-J, Niittyvuopio R, Maertens J, Passweg J, Blaise D, Byrne J, Kröger N, Bornhäuser M, Chevallier P , Bourhis J-H et al (2020) Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. Blood, 136(Supplement 1), 39-40.
Ghorashian S, Furness C, Cummins M, Snowden JA, O'Reilly MA, Roddie C, Neill L, Nicholson E, Besley C, Chaganti S , Gillson J et al (2020) Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme. Blood, 136(Supplement 1), 18-19.
Ljungman P, De La Camara R, Mikulska M, Tridello G, Aguado B, Beguin Y, Martino Bufarull R, Ciceri F, Corral LL, Crippa C , Deeren D et al (2020) COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Blood, 136(Supplement 1), 32-33.
Ljungman P, De La Camara R, Mikulska M, Tridello G, Aguado B, Beguin Y, Martino Bufarull R, Ciceri F, Corral LL, Crippa C , Deeren D et al (2020) COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Blood, 136(20), 32-33.
Burt RK, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, Snowden JA & Hartung D (2020) Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Multiple Sclerosis and Related Disorders, 45, 102404-102404.
Laurent C, Marjanovic Z, Henes J, Farge D, Badoglio M, Snowden J, Fain O, Alexander T, Oliveira MC & Mekinian A (2020) THU0312 AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS: A RETROSPECTIVE MULTICENTRE CASE-SERIES FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (EBMT). Annals of the Rheumatic Diseases, 79(Suppl 1), 385-385.
Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, van der Werf S, Knelange NS, Averbuch D, Socié G, Veelken H , Dalle J-H et al (2020) Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Acta Haematologica Polonica, 51(2), 73-80.
Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M , Montoto S et al (2020) The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation, 55(11), 2071-2076.
Das J, Gill A, Lo C, Chan-Lam N, Price S, Wharton SB, Jessop H, Sharrack B & Snowden JA (2020) A case of multiple sclerosis—like relapsing remitting encephalomyelitis following allogeneic hematopoietic stem cell transplantation and a review of the published literature. Frontiers in Immunology, 11. View this article in WRRO
Alexander T, Badoglio M, Henes J, Heesen C, Arnold R, Radbruch A, Snowden JA & Hiepe F (2020) Autologe hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen. Zeitschrift für Rheumatologie, 79(5), 419-428.
Sharrack B, Saccardi R, Alexander T, Manuela B, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K , Labopin M et al (2020) Autologous haematopoietic stem cell transplantation in multiple sclerosis and other immune-mediated neurological diseases: guidelines and recommendations of the European Society for Blood and Marrow Transplantation and the Joint Accreditation Committee of the International Society for Cellular Therapy (4540). Neurology, 94(15_supplement).
Das J, Gill A, Lo C, Chan-Lam N, Price S, Wharton S, Jessop H, Sharrack B & Snowden J (2020) Multiple sclerosis-like CNS inflammation following allogeneic haematopoietic stem cell transplantation treated with a ‘domino’ autologous haematopoietic stem cell transplantation (4687). Neurology, 94(15_supplement).
Bell S, Snowden J, Jessop H, Das J, Ismail A & Sharrack B (2020) The use of Autologous Haemopoetic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis after Alemtuzumab treatment failure: a case series (2073). Neurology, 94(15_supplement).
Schiepatti A, Sanders DS, Aziz I, De Silvestri A, Goodwin J, Key T, Quaye L, Giuffrida P, Vanoli A, Paulli M , Cross SS et al (2020) Clinical phenotype and mortality in patients with idiopathic small bowel villous atrophy: a dual-centre international study. European Journal of Gastroenterology & Hepatology. View this article in WRRO
Smith R, Snowden J & Akil M (2020) P149 Haematopoietic stem cell transplantation in systemic sclerosis: Sheffield Teaching Hospitals’ experience. Rheumatology, 59(Supplement_2).
Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S , Peffault de Latour R et al (2020) The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplantation, 55(8), 1604-1613.
Penny HA, Baggus EMR, Rej A, Snowden JA & Sanders DS (2020) Non-responsive coeliac disease : a comprehensive review from the NHS England national centre for refractory coeliac disease. Nutrients, 12(1). View this article in WRRO
Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D , Poirel HA et al (2020) Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 55(4), 838-839.
Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M , Kersten MJ et al (2020) Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 105(2), 297-316.
Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D & Snowden JA (2020) Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 55(7), 1473-1475.
Domingo-Domènech E, Boumendil A, Climent F, Sengeloev H, Wahlin B, Wattad W, Arat M, Finel H, Schapp N, Ganser A , Yeshurun M et al (2020) Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. Bone Marrow Transplantation, 55(4), 796-803.
Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M, Hsu K, Madrigal JA , Maiers MJ et al (2020) Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. The Lancet Haematology, 7(1), e50-e60.
Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D , Poirel HA et al (2020) Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 55(4), 681-694.
González-Barca E, Boumendil A, Blaise D, Trněný M, Masszi T, Finel H, Michieli MG, Bittenbring JT, Gritti G, Snowden JA , Bishton M et al (2020) Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 55(2), 393-399.
Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P , Averbuch D et al (2020) Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplantation, 55(1), 126-136.
Sandler RD, Carter S, Kaur H, Francis S, Tattersall RS & Snowden JA (2020) Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT)—time to reappraise with modern diagnostic and treatment strategies?. Bone Marrow Transplantation, 55(2), 307-316.
Alexander T, Samuelson C, Daikeler T, Henes J, Akil M, Skagerlind L, Ehninger G, Jantunen E, Badoglio M, Farge D & Snowden JA (2020) Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. Bone Marrow Transplantation, 55(7), 1512-1515.
Gratwohl A, Snowden JA & Brand R (2020) Gender gaps in transplantation. British Journal of Haematology, 190(2).
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E , Labopin M et al (2019) Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology, 19(1). View this article in WRRO
Czerw T, Malpassuti V, Iacobelli S, Koster L, Kröger N, Robin M, Maertens J, Chevallier P, Mielke S, Poire X , Snowden JA et al (2019) Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT. Blood, 134(Supplement_1), 3338-3338.
Bazarbachi AH, Al Hamed R, Labopin M, Halaburda K, Labussière-Wallet H, Bernasconi P, Schroyens W, Gandemer V, Schaap N, Rohrlich PS , Jindra P et al (2019) Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party. Blood, 134(Supplement_1), 4483-4483.
Saccardi R, Badoglio M, Burman J, Helbig G, Kazmi MA, Mancardi G, Mielke S, Moore J, Muraro P, Sanz J , Sharrack B et al (2019) BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. Blood, 134(Supplement_1), 3313-3313.
Waszczuk-Gajda A, Wang J, de Wreede LC, Sirait T, Ozkurt ZN, Snowden JA, Dreger P, Illés Á, Arat M, Bulabois C-E , Baurmann H et al (2019) Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT. Blood, 134(Supplement_1), 4574-4574.
Creasey T, Barretta E, Kirkwood AA, Schwab C, Patrick P, Clifton-Hadley L, Wrench B, Menne TF, McMillan AK, Morley NJ , Snowden JA et al (2019) Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. Blood, 134(Supplement_1), 2746-2746.
Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, Ashton J, Brown JM, Huddart R, Coleman RE , Snowden JA et al (2019) Testosterone replacement in young male cancer survivors : a 6-month double-blind randomised placebo-controlled trial. PLOS Medicine, 16(11). View this article in WRRO
Ismail A, Sharrack B, Saccardi R, Moore JJ & Snowden JA (2019) Autologous haematopoietic stem cell therapy for multiple sclerosis. Current Opinion in Supportive and Palliative Care, 13(4), 394-401.
Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery AR , Kuball J et al (2019) Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019.. Bone Marrow Transplantation, 54(10), 1525-1552. View this article in WRRO
Miller PDE, Snowden JA, De Latour RP, Iacobelli S, Eikema D-J, Knol C, Marsh JCW, Rice C, Koh M, Fagioli F , Chaganti S et al (2019) Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia : a joint study of the autoimmune diseases and severe aplastic anaemia working parties (ADWP/SAAWP) of the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplantation. View this article in WRRO
Francis S, Thomas S, Luben R, Sousos N, Mead A, Snowden JA & Zeidler MP (2019) Low‐dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms. British Journal of Haematology, 187(3).
Gratwohl A, Duarte R, Snowden JA, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix HT, Grath EM, Mohty M , Kroeger N et al (2019) Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. EClinicalMedicine, 15, 33-41.
Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G , Hari P et al (2019) Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematology/Oncology and Stem Cell Therapy.
Snowden JA, Badoglio M & Alexander T (2019) The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Review of Clinical Immunology, 15(10), 981-985.
Halkes C, Wreede LC, Knol C, Simand C, Aljurf M, Tbakhi A, Vazquez L, Bloor A, Wagner‐Drouet E, Vural F , Bodova I et al (2019) Allogeneic stem cell transplantation for acquired pure red cell aplasia. American Journal of Hematology, 94(11).
Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C , Galimard J-E et al (2019) Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. The Lancet Haematology, 6(11), e573-e584.
Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D , Dhanapal V et al (2019) Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. Journal of Clinical Oncology, 37(19), 1617-1628. View this article in WRRO
Ros-Soto J, Snowden JA, Salooja N, Gilleece M, Parker A, Greenfield DM, Anthias C, Alfred A, Harrington A, Peczynski C , Peggs K et al (2019) Current Practice in Vitamin D Management in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 25(10), 2079-2085.
Morley N, Kirkwood A, Moorman A, Clifton-Hadley L, Moreira L, Rowntree C, Wrench B, Marwood E, Patrick P, Snowden JA , Marks DI et al (2019) RESULTS FROM UKALL60+, A UK PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA. HemaSphere, 3, 38-39.
Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale GA , Hari P et al (2019) Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation, 25(12), 2322-2329.
Horton MC, Nopoulos P, Nance M, Landwehrmyer GB, Barker RA, Squitieri F, Burgunder J-M & Quarrell O (2019) Assessment of the Performance of a Modified Motor Scale as Applied to Juvenile Onset Huntington’s Disease. Journal of Huntington's Disease, 8(2), 181-193.
Das J, Sharrack B & Snowden JA (2019) Correction to: Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists. Current Hematologic Malignancy Reports, 14(2), 136-136.
Das J, Sharrack B & Snowden JA (2019) Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists. Current Hematologic Malignancy Reports, 1-9. View this article in WRRO
Cook G, Royle K, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D , Tholouli E et al (2019) The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT / UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial. British Journal of Haematology, 185(3), 450-467.
Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Kuball J, Lankester A, Montoto S, de Latour RP , Snowden JA et al (2019) The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation, 1-11. View this article in WRRO
Jessop H, Farge D, Saccardi R, Alexander T, Rovira M, Sharrack B, Greco R, Wulffraat N, Moore J, Kazmi M , Badoglio M et al (2019) General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 1-10. View this article in WRRO
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA , Carlson K et al (2019) Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 321(2), 165-174. View this article in WRRO
Miller PDE, de Silva TI, Leonard H, Anthias C, Hoschler K, Goddard K, Peggs K, Madrigal A & Snowden JA (2019) A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant. Vaccine, 37(3), 452-457. View this article in WRRO
Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E , Tholouli E et al (2019) Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival. British Journal of Haematology. View this article in WRRO
Hayden PJ, Sirait T, Koster L, Snowden JA & Yakoub-Agha I (2019) An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. Current Research in Translational Medicine, 67(3), 79-88.
Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H , Dalle JH et al (2019) Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. American Journal of Hematology, 94(1), 80-86.
Scott SD, Fletcher M, Whitehouse H, Whitby L, Yuan C, Mazzucchelli S, Lin P, de Tute R, Dorwal P, Wallace PK , Tembhare P et al (2019) Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter‐laboratory study: Is it ready for primetime use?. Cytometry Part B: Clinical Cytometry, 96(3), 201-208.
Ros-Soto J, Anthias C, Madrigal A & Snowden JA (2019) Vitamin D: is it important in haematopoietic stem cell transplantation? A review. Bone Marrow Transplantation, 54(6), 810-820.
Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE & Greenfield DM (2019) Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer, 27(5), 1755-1763. View this article in WRRO
Spearing R, Bradstock K & Snowden JA (2019) Derek Nigel John Hart (1952–2017). Bone Marrow Transplantation, 54(2), 173-174.
Striha A, Ashcroft AJ, Hockaday A, Cairns DA, Boardman K, Jacques G, Williams C, Snowden JA, Garg M, Cavenagh J , Yong K et al (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19(1). View this article in WRRO
Robinson S, Boumendil A, Khvedelidze I, Finel H, Peggs K, Malladi RK, Potter V, Tsoulkani A, Vandenberghe E, Chalandon Y , Finke J et al (2018) Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT. Blood, 132(Supplement 1), 2070-2070.
Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
Paton-Hough J, Tazzyman S, Evans H, Lath D, Down JM, Green AC, Snowden JA, Chantry AD & Lawson MA (2018) Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research. View this article in WRRO
Mahmoodi N, Bekker HL, King NV, Hughes J, Jones GL & Team CFMR (2018) Are publicly available internet resources enabling women to make informed fertility preservation decisions before starting cancer treatment: An environmental scan? 11 Medical and Health Sciences 1117 Public Health and Health Services. BMC Medical Informatics and Decision Making, 18(1). View this article in WRRO
Joyutpal D, John S, Sona M, Simon B, Helen J & Basil S (2018) THUR 194 Autologous haematopoietic stem cell transplant in ms. Journal of Neurology, Neurosurgery & Psychiatry, 89(10), A28.2-A28.
Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J , Onida F et al (2018) Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. Journal of Crohn's and Colitis, 12(9), 1097-1103. View this article in WRRO
Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, Dufour C, Kröger N, Kuball J, Lankester A , Montoto S et al (2018) Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 53(9), 1139-1148. View this article in WRRO
(2018) Bone Research Society Abstracts. JBMR plus, 2(Suppl ), 1-50.
Miller PDE, Forster AS, de Silva TI, Leonard H, Anthias C, Mayhew M, Klammer M, Paskar S, Hurst E, Peggs K , Madrigal A et al (2018) Sociodemographic and psychological determinants of influenza vaccine intention among recipients of autologous and allogeneic haematopoietic stem cell transplant: a cross-sectional survey of UK transplant recipients using a modified health belief model. BMJ Open, 8(8), e021222-e021222. View this article in WRRO
Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, Muraro PA & Lindsay JO (2018) Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist. Clinical Medicine, 18(4), 329-334. View this article in WRRO
Paviglianiti A, Tozatto Maio K, Rocha V, Gehlkopf E, Milpied N, Esquirol A, Chevallier P, Blaise D, Gac A-C, Leblond V , Cahn JY et al (2018) Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. Biology of Blood and Marrow Transplantation, 24(11), 2265-2270.
Alexander T, Farge D, Badoglio M, Lindsay JO, Muraro PA & Snowden JA (2018) Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms. Journal of Autoimmunity, 92, 35-46.
Mohty M, Duarte RF, Kuball J, Bader P, Basak GW, Bonini C, Carreras E, Chabannon C, Dufour C, Gennery A , Lankester A et al (2018) Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. Bone Marrow Transplantation, 53(12), 1548-1552.
Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T & Snowden JA (2018) Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn’s Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD—Low Intensity Therapy Evaluation Study Investigators. Frontiers in Immunology, 9. View this article in WRRO
Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M , Lindsay JO et al (2018) Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT.. Journal of Crohn's and Colitis, 12(4), 476-488. View this article in WRRO
Keen C, Skilbeck J, Ross H, Smith L, Collins K, Dixey J, Walters S, Greenfield D, Snowden J & Mawson S (2018) Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study. BMJ Open, 8. View this article in WRRO
Cesaro S, Tridello G, Blijlevens N, Ljungman P, Craddock C, Michallet M, Martin A, Snowden JA, Mohty M, Maertens J , Passweg J et al (2018) Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. Clinical Infectious Diseases, 67(4), 564-572.
Gagelmann N, Eikema D-J, Iacobelli S, Koster L, Nahi H, Stoppa A-M, Masszi T, Caillot D, Lenhoff S, Udvardy M , Crawley C et al (2018) Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica, 103(5), 890-897.
Brierley C, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J , Onida F et al (2018) OP021 Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party. Journal of Crohn's and Colitis, 12(supplement_1), S014-S015.
Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M , Lindsay J et al (2018) DOP057 ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn’s disease: Summary of the ECCO-EBMT joint review. Journal of Crohn's and Colitis, 12(supplement_1), S070-S071.
Holbro A, Baldomero H, Lanza F, Chabannon C, Snowden JA, Buser A, Infanti L, Worel N, Sureda A, Badoglio M , Passweg J et al (2018) Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. Cytotherapy, 20(3), 453-460.
Ring ES, Lawson MA, Snowden JA, Jolley I & Chantry AD (2018) New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International, 102(2), 196-209. View this article in WRRO
Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, Burman J, Moore J, Rovira M, Wulffraat NM , Kazmi M et al (2017) Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases.. Blood Advances, 1(27), 2742-2755. View this article in WRRO
Shouval R, Fein J, Labopin M, Kröger N, Duarte RF, Bader P, Chiara B, Kuball J, Basak G, Dufour C , Lankester A et al (2017) Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. Blood, 130(Suppl_1), 668-668.
Chabannon C, Kuball J, Mcgrath E, Bader P, Dufour C, Lankester A, Basak GW, Montoto S, Nagler A, Snowden JA , Styczynski J et al (2017) CAR-T cells: the narrow path between hope and bankruptcy?. Bone Marrow Transplantation, 52(12), 1588-1589.
Martin M, Fornecker L-M, Marcellin L, Mousseaux E, Hij A, Snowden JA, Farge D & Martin T (2017) Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. Bone Marrow Transplantation, 52(12), 1674-1677.
Miller PDE, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A & Snowden JA (2017) Erratum: Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes. Bone Marrow Transplantation, 52(7), 1082-1082.
Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M , Raj K et al (2017) UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy. Journal of Clinical Apheresis.
Chinnaiya K, Lawson MA, Thomas S, Haider M-T, Down J, Chantry AD, Hughes D, Green A, Sayers JR, Snowden JA & Zeidler MP (2017) Low-dose methotrexate in myeloproliferative neoplasm models.. Haematologica, 102, e336-e339. View this article in WRRO
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA , Samarasinghe S et al (2017) British Committee for Standards in Haematology guidelines for aplastic anemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of 20 × 10(9) /L - RESPONSE to Yan et al.. Br J Haematol.
Farge D, Burt RK, Oliveira M-C, Mousseaux E, Rovira M, Marjanovic Z, de Vries-Bouwstra J, Del Papa N, Saccardi R, Shah SJ , Lee DC et al (2017) Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.. Bone Marrow Transplantation. View this article in WRRO
Hamblin A, Greenfield DM, Gilleece M, Salooja N, Kenyon M, Morris E, Glover N, Miller P, Braund H, Peniket A , Shaw BE et al (2017) Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes. Bone Marrow Transplantation, 52, 889-894. View this article in WRRO
Snowden JA, O'Connell S, Hawkins J, Dalley C, Jack A, Mannari D, McNamara C, Scott M, Shenton G, Soilleux E , Macbeth F et al (2017) Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS).. J Clin Pathol. View this article in WRRO
Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T , Snowden JA et al (2017) Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.. Br J Haematol.
Kühl J-S, Suarez F, Gillett GT, Hemmati PG, Snowden JA, Stadler M, Vuong GL, Aubourg P, Köhler W & Arnold R (2017) Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy. Brain, 140(4), 953-966. View this article in WRRO
Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, Kuball J, Chabannon C & Mohty M (2017) JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement.. Bone Marrow Transplant. View this article in WRRO
Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, Casanova B, Ouyang J, Bembeeva R, Haas J , Bader P et al (2017) Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation.
Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F , Montoto S et al (2017) Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report.. Bone Marrow Transplant. View this article in WRRO
Snowden JA, Greenfield DM, Bird JM, Boland E, Bowcock S, Fisher A, Low E, Morris M & Pratt G (2017) Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. British Journal of Haematology, 176(6), 888-907. View this article in WRRO
Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, Greinix HT, Mc Grath E, Kroeger N, Lanza F , Nagler A et al (2017) Alloreactivity: The janus-face of hematopoietic stem cell transplantation.. Leukemia.
Jones GL, Hughes J, Mahmoodi N, Greenfield D, Brauten-Smith G, Skull J, Gath J, Yeomanson D, Baskind E, Snowden JA , Jacques RM et al (2017) Observational study of the development and evaluation of a fertility preservation patient decision aid for teenage and adult women diagnosed with cancer: the Cancer, Fertility and Me research protocol. BMJ Open, 7(3). View this article in WRRO
Snowden JA & Hill GR (2017) Conditioning regimens for autologous haematopoietic stem cell transplantation - can natural killer cell therapy help?. British Journal of Haematology. View this article in WRRO
Lawless S, Iacobelli S, van Biezen A, Koster L, Chevallier P, Blaise D, Foa R, Tabrizi R, Schaap N, Lenhoff S , Russell N et al (2017) Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. Clinical Lymphoma Myeloma and Leukemia, 17(1), e23-e23.
Miller PD, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A & Snowden JA (2017) Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.. Bone Marrow Transplant. View this article in WRRO
Watson MB, Clouston HJ, Snowden JA, Wilson G, Durkie M, Ward R, Kaur H, Travis D & Barnett D (2017) Lineage-specific chimerism monitoring after allogeneic haematopoietic stem cell transplantation: do we really know what we are measuring?. British Journal of Haematology, 176(1), 139-141.
Burt RK, Snowden JA, Burman J, Oliveira MC & Sharrack B (2017) Blogs cannot separate wheat from chaff. Science, 358(6363), 602.1-602.
Shanklin VE, Snowden JA & Greenfield DM (2016) Late treatment effects following bone marrow transplant: Efficacy of implementing international guidelines. European Journal of Cancer Care. View this article in WRRO
Bell SM, Sharrack B & Snowden J (2016) Autologous hematopoietic cell transplantation in multiple sclerosis.. Expert Opin Biol Ther. View this article in WRRO
DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN , Gilleece M et al (2016) Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplantation. View this article in WRRO
Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J , Hunter H et al (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology, 3(7), e340-e351. View this article in WRRO
Parrish C, Morris CTCM, Williams CD, Cairns DA, Cavenagh J, Snowden JA, Ashcroft J, Cavet J, Hunter H, Bird JM , Chalmers A et al (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22(6), 1009-1016. View this article in WRRO
Oliveira MC, Labopin M, Henes J, Moore J, Papa ND, Cras A, Sakellari I, Schroers R, Scherer HU, Cuneo A , Kyrcz-Krzemien S et al (2016) Erratum: Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?. Bone Marrow Transplantation, 51(6), 889-889.
Kelsey PJ, Oliveira M-C, Badoglio M, Sharrack B, Farge D & Snowden JA (2016) Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice. Current Research in Translational Medicine, 64(2), 71-82.
Samuelson C, O'Toole L, Boland E, Greenfield D, Ezaydi Y, Ahmedzai SH & Snowden JA (2016) High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for ‘late effects’ screening and preventive strategies. Hematology, 21(5), 272-279. View this article in WRRO
DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN , Gilleece M et al (2016) Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 22(8), 1493-1503. View this article in WRRO
Baliousis M, Rennoldson M & Snowden JA (2016) Psychological interventions for distress in adults undergoing haematopoietic stem cell transplantation: a systematic review with meta‐analysis. Psycho-Oncology, 25(4), 400-411.
Berndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, Nieters A, Kelly RS, Smedby KE, Monnereau A , Cozen W et al (2016) Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 7(1), 10933-10933. View this article in WRRO
Snowden JA (2016) Rebooting autoimmunity with autologous HSCT. Blood, 127(1), 8-10.
Snowden JA, Danby R, Ruggeri A, Marks DI, Hough RE, Pagliuca A, Potter M, Russell N, Craddock C, Clark A , Miller P et al (2016) Unrelated Cord Blood Transplantation in adults: Evolution, experience and long-term outcomes in the UK National Health Service : A retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. British Journal of Haematology, 172(3), 478-481.
Oliveira MC, Labopin M, Henes J, Moore J, Papa ND, Cras A, Sakellari I, Schroers R, Scherer HU, Cuneo A , Kyrcz-Krzemien S et al (2016) Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?. Bone Marrow Transplant, 51(4), 501-505. View this article in WRRO
Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS , Crawley C et al (2016) Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: An update on cord blood unit selection, donor selection algorithms and conditioning protocols. British Journal of Haematology, 172(3), 360-370.
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G , Snowden JA et al (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. British Journal of Haematology, 172(2), 187-207.
Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R , Vyas P et al (2016) Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Biology of Blood and Marrow Transplantation, 22(2), 385-390.
Greenfield DM, Blewitt A, Coleman RE, Walsh JS, Snowden JA, Ross RJM & Han TS (2016) Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Clinical Endocrinology, 84(2), 296-304.
Cook G, Williams C, Cairns DA, Hockaday A, Cavenagh J, Snowden JA, Parrish C, Yong KL, Cavet J, Hunter H , Bird J et al (2015) A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial. Blood, 126(23), 394-394.
Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, Ljungman P, McGrath E, Mohty M, Nagler A , Rambaldi A et al (2015) Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. EBioMedicine, 2(12), 2101-2109. View this article in WRRO
Sezer O, Terpos E, Hajek R, Sucak G, Cagirgan S, Linkesch W, Akay OM, Armbrecht G, Plesner T, Snowden JA , Nahi H et al (2015) Improved tumor response and survival outcomes with post-transplant bortezomib (Btz) consolidation versus observation (Obs) alone in patients with newly diagnosed multiple myeloma (MM): Results from a randomized, open-label, multicenter, parallel-group phase 2 study. Clinical Lymphoma Myeloma and Leukemia, 15, e129-e130.
Pratt G, Bowcock S, Chantry A, Cook G, Jackson G, Lai M, Low E, Mulholland N, Owen R, Rabin N , Ramasamy K et al (2015) Time to redefine Myeloma. British Journal of Haematology, 171(1), 1-10.
Thomas SJ, Snowden JA, Zeidler MP & Danson SJ (2015) The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. British Journal of Cancer, 113(3), 365-371. View this article in WRRO
Thomas S, Fisher KH, Snowden JA, Danson SJ, Brown S & Zeidler MP (2015) Methotrexate Is a JAK/STAT Pathway Inhibitor. PLOS ONE, 10(7). View this article in WRRO
Thomas S, Fisher K, Snowden J, Danson S, Brown S & Zeidler M (2015) Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms. The Lancet, 385, S98-S98.
Alexander T, Bondanza A, Muraro PA, Greco R, Saccardi R, Daikeler T, Kazmi M, Hawkey C, Simoes BP, Leblanc K , Fibbe WE et al (2015) SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplantation, 50(2), 173-180. View this article in WRRO
Dalley C, Basarir H, Wright JG, Fernando M, Pearson D, Ward SE, Thokula P, Krishnankutty A, Wilson G, Dalton A , Talley P et al (2015) Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. Journal of Clinical Pathology, 68(4), 292-300. View this article in WRRO
Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, Pearce L, Jackson T, Clouston H, Sproul A , Keen L et al (2015) Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): Technical recommendations for the use of Short Tandem Repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service. British Journal of Haematology, 168(1), 26-37. View this article in WRRO
Snarski E, Snowden JA, Oliveira MC, Simoes B, Badoglio M, Carlson K, Burman J, Moore J, Rovira M, Clark RE , Saiz A et al (2015) Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplantation, 50(2), 216-220.
Sloot S, Boland J, Snowden JA, Ezaydi Y, Foster A, Gethin A, Green T, Chopra L, Verhagen S, Vissers K , Engels Y et al (2015) Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. Supportive Care in Cancer, 23(3), 671-678. View this article in WRRO
Pratt G, Jenner M, Owen R, Snowden JA, Ashcroft J, Yong K, Feyler S, Morgan G, Cavenagh J, Cook G , Low E et al (2014) Updates to the guidelines for the diagnosis and management of multiple myeloma. British Journal of Haematology, 167(1), 131-133.
Walker RE, Lawson MA, Buckle CH, Snowden JA & Chantry AD (2014) Myeloma bone disease: pathogenesis, current treatments and future targets. British Medical Bulletin, 111(1), 117-138.
Dharmagunawardena R, Pearce RM, Thomas G, Kirkland K, Perry J, Apperley JF, Medd P, Wilson KMO, Orchard K, Jackson G , Snowden JA et al (2014) A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function. Bone Marrow Transplantation, 49(11), 1442-1443.
Greenfield DM, Boland E, Ezaydi Y, Ross RJ, Ahmedzai SH & Snowden JA (2014) Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.. Bone Marrow Transplant.
Snowden JA, Ansari A, Sachchithanantham S, Jackson G, Thompson N, Lobo A, Sanderson J & Kazmi M (2014) Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis.. QJM, 107(11), 871-877.
Boland EG, Boland JW, Ezaydi Y, Greenfield DM, Ahmedzai SH & Snowden JA (2014) Holistic needs assessment in advanced, intensively treated multiple myeloma patients.. Support Care Cancer, 22(10), 2615-2620.
Greenfield DM, Boland E, Ezaydi Y, Ross RJM, Ahmedzai SH, Snowden JA & Late Effects Group (2014) Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.. Bone Marrow Transplant, 49(7), 907-912.
Tridente A, Browett K, Hall J, Sorour Y, Snowden J & Webber S (2014) Predictors of outcome in patients with haematological malignancies admitted to critical care. Critical Care, 18(Suppl 1), P41-P41.
Cook G, Parrish C, O'Connor S, Williams C, Brown JM, Cairns DA, Fletcher M, Chalmers A, Cavenagh J, Snowden JA , Ashcroft AJ et al (2014) High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. The Lancet Oncology.
Rabin N, Lai M, Pratt G, Morgan G, Snowden J, Bird J, Cook G, Bowcock S, Owen R, Yong K , Wechalaker A et al (2014) United kingdom myeloma forum position statement on the use of consolidation and maintenance treatment in myeloma. International Journal of Laboratory Hematology.
Pechlivanoglou P, Le HH, Daenen S, Snowden JA & Postma MJ (2014) Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: A systematic review. Journal of Antimicrobial Chemotherapy, 69(1), 1-11.
Horne B, Gilleece M, Jackson G, Snowden JA, Liebersbach S, Velikova G & Wright P (2014) Psychosocial supportive care services for haematopoietic stem cell transplant patients; a service evaluation of three UK transplant centres.. Eur J Cancer Care (Engl), 23(3), 349-362.
Marsh JC, Pearce RM, Koh MBC, Lim Z, Pagliuca A, Mufti GJ, Perry J, Snowden JA, Vora AJ, Wynn RT , Russell N et al (2014) Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.. Bone Marrow Transplant, 49(1), 42-48.
Boland EG, Selvarajah D, Hunter M, Ezaydi Y, Tesfaye S, Ahmedzai SH, Snowden JA & Wilkinson ID (2014) Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging study.. PLoS One, 9(5), e96474. View this article in WRRO
Snarski E, Snowden JA, Badoglio M, Carlson K, Burman J, Oliveira MC, Moore J, Tan J, Rovira M, Clark RE , Saiz A et al (2013) Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP). Blood, 122(21), 4640-4640.
Snowden JA, Danby R, Ruggeri A, Marks DI, Hough RE, Pagliuca A, Potter M, Russell N, Craddock C, Clark A , Gluckman E et al (2013) Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord. Blood, 122(21), 3394-3394.
Ashcroft J, de Tute RM, Cairns DA, Fletcher M, Owen RG, Rawstron A, O'Connor SJM, Williams CD, Snowden JA, Cavenagh JD , Parrish C et al (2013) The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. Blood, 122(21), 3378-3378.
Cook G, Williams CD, Cairns DA, Fletcher M, Cavenagh JD, Snowden JA, Parrish C, Ashcroft J, Yong KL, Cavet J , Hunter H et al (2013) A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. Blood, 122(21), 765-765.
Cook G, Ashcroft J, Williams CD, Cairns DA, Fletcher M, Parrish C, Cavenagh JD, Snowden JA, O'Connor SJ, Owen RG , Brown J et al (2013) Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. Blood, 122(21), 1884-1884.
Berndt SI, Chung CC, Chanock SJ, Rothman N, Skibola CF, Conde L, Joseph V, Klein RJ, Camp NJ, Cannon-Albright LA , Nieters A et al (2013) Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics. View this article in WRRO
Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, Sica S, Trneny M, Snowden JA, Kanfer E , Milpied N et al (2013) Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.. Ann Oncol, 24(9), 2430-2434.
Cook G, Williams C, Szubert A, Yong K, Cavet J, Hunter H, Bird J, Bell S, O'Connor S, Cavenagh J , Snowden JA et al (2013) Superior response durability following a second autologous stem cell transplant (ASCT) for relapsed multiple myeloma (MM): results from the BSBMT/UKMF myeloma X (Intensive) trial. BRITISH JOURNAL OF HAEMATOLOGY, 161, 8-8.
Rabusin M, Snowden JA, Veys P, Quartier P, Dalle JH, Dhooge C, Di Bartolomeo P, Gonzalez-Vicent M, Gibson B, Iriondo A , Juergens H et al (2013) Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. Biology of Blood and Marrow Transplantation, 19(4), 666-669.
Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH & Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life.. J Pain Symptom Manage, 46(5), 671-680.
Murng SHK, Follows L, Whitfield P, Snowden JA, Swallow K, Green K, Sargur R & Egner W (2013) Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma. Clinical and Experimental Immunology, 171(2), 201-209.
Snowden JA, Akil M & Kiely DG (2013) Improving safety in autologous HSCT for systemic sclerosis.. Lancet, 381(9872), 1081-1083.
Morris TCM, Williams C, Bell S, Fletcher M, Szubert A, Brown J, Cavenagh J, Snowden J, Ashcroft J, Yong K , Cavet J et al (2013) Patient perceptions of second transplants in myeloma: Impact on recruitment in the british society of blood and marrow transplantation/UK myeloma forum myeloma X relapse (Intensive) trial. British Journal of Haematology.
Gesundheit B, Rosenzweig JP, Naor D, Melamed M, Lerer B, Zachor DA, Procházka V, Kristt DA, Steinberg A, Shulman C , Hwang P et al (2013) Immunological and autoimmune considerations of Autism Spectrum Disorders. Journal of Autoimmunity.
Pratt G, Bowcock S, Lai M, Bell S, Bird J, D'Sa S, Yong K, Cavenagh J, Cook G, Morgan G , Davies F et al (2013) United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. International Journal of Laboratory Hematology.
Alix JJP, Blackburn DJ, Sokhi D, Craven I, Sharrack B & Snowden JA (2013) Autologous hematopoietic stem cell transplantation following pulsed cyclophosphamide in a severely disabled patient with malignant multiple sclerosis.. J Neurol, 260(3), 914-916.
Farge-Bancel D, Marjanovic Z, Hadj Khelifa S, Ruggeri A-L, Martin T, Deligny C, Duran J-M, Sarrot-Reynauld F, Adoue D, Constans J , Philippe P et al (2012) Suivi à long terme des patients traités par autogreffe de moelle pour maladie autoimmune sévère. La Revue de Médecine Interne, 33, A79-A80.
Bansal T, Garg A, Snowden JA & McKane W (2012) Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias. Nephron - Clinical Practice, 120(4).
Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, Denton C, Hawkey C, Labopin M, Mancardi G , Martin R et al (2012) Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European group for blood and marrow transplantation. Bone Marrow Transplantation, 47(6), 770-790.
Patrick KL, Snowden JA, Wilson G, Collins N & Dalley CD (2012) Long term lympho-haematopoietic reconstitution by umbilical cord blood stem cells following primary graft failure and autologous rescue.. Br J Haematol, 158(3), 419-420.
Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P, Clark RE, Kazmi M, Abinun M, Jackson GH , Mackinnon S et al (2012) Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.. Br J Haematol, 157(6), 742-746.
Nield A, Ward S, Goddard Y, Harrison S, McGoldrick R, Downes T, Ezaydi Y, Jessop H, Fairley V, Beadle H , Ritson M et al (2012) Using the clinical microsystems approach to enable ambulatory care to be a treatment option for patients with haematological malignancies. BONE MARROW TRANSPLANTATION, 47, S459-S459.
Cachia E, Eiser C, Ezaydi Y, Greenfield D, Ahmedzai S & Snowden J (2012) A study of pain, peripheral neuropathy and psychosocial late effects in multiple myeloma patients. BMJ Supportive & Palliative Care, 2(Suppl 1), A3.2-A3.
Samuelson C, Dalley C, Ezaydi Y, Snowden JA & Collins N (2012) Treatment of relapsed myelodysplastic syndrome following double umbilical cord blood transplantation with interferon alpha and 5-azacytidine. British Journal of Haematology.
Tailor IK, Cook J, Reilly JT, Dalley CD, Ezaydi Y, Kelsey PJ & Snowden JA (2012) Acute myeloid leukaemia associated with Muir-Torre variant of hereditary non-polyposis colon cancer (HNPCC): Implications for inherited and acquired mutations in DNA mismatch repair genes. British Journal of Haematology, 156(2), 289-291.
Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M , Snowden JA et al (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood, 119(14), 3361-3369.
Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P, Clark RE, Kazmi M, Abinun M, Jackson GH , MacKinnon S et al (2012) Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: Analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. British Journal of Haematology, 157(6), 742-746.
Taylor N, Absolom K, Snowden J, Eiser C & Late Effects Group Sheffield (2012) Need for psychological follow-up among young adult survivors of childhood cancer.. Eur J Cancer Care (Engl), 21(1), 52-58.
Tailor IK, Akil M, Rennie I, Ross RJ & Snowden JA (2012) Reconstitution Graves' disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis.. QJM, 105(4), 369-371.
Marsh JCW, Pearce RM, Koh MB, Tang D, Lim Z, Pagliuca A, Mufti GJ, Snowden J, Vora AJ, Gibson B , Gilleece MH et al (2011) National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). Blood, 118(21), 52-52.
Dennis M, Goodyear O, Loke J, Jilani N, Siddique S, Ryan G, Khanum R, Snowden J, Griffiths M, Russell NH , Yin J et al (2011) Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response. Blood, 118(21), 324-324.
Snowden JA, Ahmedzai SH, Ashcroft J, D'Sa S, Littlewood T, Low E, Lucraft H, Maclean R, Feyler S, Pratt G , Bird JM et al (2011) Guidelines for supportive care in multiple myeloma 2011.. Br J Haematol, 154(1), 76-103.
Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP , Wulffraat N et al (2011) Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: A retrospective study of the EBMT Autoimmune Disease Working Party. Blood, 118(6), 1693-1698.
Snowden JA, Pamphilon D, Kirkland K & Jackson GH (2011) Such data can benefit medicine as well as surgery. BMJ, 342(7802).
Morris C, Cook G, Streetly M, Kettle P, Drake M, Quinn M, Cavet J, Tighe J, Kazmi M, Ashcroft J , Cook M et al (2011) Re-transplantation after bortezomib-based therapy. British Journal of Haematology, 153(5), 666-668.
Hossain R, Snowden JA, Bansal T & McKane W (2011) Safety and efficacy of high dose melphalan and autologous stem cell transplantation prior to renal allograft in end- stage renal failure secondary to Monoclonal Immunoglobulin Deposition Disease. Cellular Therapy and Transplantation, 3(10).
Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F , Morgan G et al (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology.
Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F , Morgan G et al (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 154(1), 32-75.
Daikeler T, Labopin M, di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze C-P , Wulffraat N et al (2010) Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. Blood, 116(21), 2322-2322.
Nabhan SK, Bitencourt MA, Duval M, Abecasis M, Dufour C, Boudjedir K, Rocha V, Socié G, Passweg J, Goi K , Sanders J et al (2010) Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients.. Haematologica, 95(10), 1783-1787.
Walsh JS, Eastell R, Coleman RE, Snowden JA, Shalet SM, Ross RJ & Greenfield DM (2010) Increased fat mass may be protective of bone mass in young male cancer survivors. Bone, 47, S189-S190.
Martinez C, Canals C, Alessandrino E, Karakasis D, Leone G, Trneny M, Snowden J, Apperley J, Milpied N & Sureda A (2010) Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT.. Journal of Clinical Oncology, 28(15_suppl), 8060-8060.
Martinez C, Canals C, Alessandrino E, Karakasis D, Leone G, Trneny M, Snowden J, Apperley J, Milpied N, Sureda A & EBMT LWP (2010) Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Ansari A, Patel N, Sachchithanantham S, Jackson G, Thompson N, Snowden J, Lobo AJ, Sanderson JD & Kazmi M (2010) T1747 Autologous Stem Cell Transplantation for Severe, Treatment-Refractory Crohn's Disease: the UK Experience to Date. Gastroenterology, 138(5), S-570.
Arachchillage DRJ, Dalley CD, Reilly JT, Wilson G, Collins N & Snowden JA (2010) Long-term dual donor derived haematopoietic reconstitution following double unrelated cord blood transplantation - single unit dominance is not always the case. BRIT J HAEMATOL, 149(2), 298-299.
Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Snowden JA, Shalet SM, DeRogatis LR & Ross RJM (2010) Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study.. Cancer, 116(6), 1592-1601.
Burt RK, Abinun M, Farge-Bancel D, Fassas A, Hiepe F, Havrdová E, Ikehara S, Loh Y, Champ AMDH, Voltarelli JC , Snowden J et al (2010) Risks of immune system treatments. Science, 328(5980), 825-826.
Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P , Clark A et al (2010) Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: Pharmacokinetics, GVHD, and immune reconstitution. Blood, 116(16), 3080-3088.
Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E , Kottaridis P et al (2010) Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95(6), 989-995.
Greenfield DM, Absolom K, Eiser C, Walters SJ, Michel G, Hancock BW, Snowden JA & Coleman RE (2009) Follow-up care for cancer survivors: the views of clinicians.. Br J Cancer, 101(4), 568-574. View this article in WRRO
Absolom K, Eiser C, Michel G, Walters SJ, Hancock BW, Coleman RE, Snowden JA & Greenfield DM (2009) Follow-up care for cancer survivors: views of the younger adult.. Br J Cancer, 101(4), 561-567. View this article in WRRO
Kazmi M, Ansari A, Sanderson J, Jackson G, Lobo A, Thompson N & Snowden J (2009) Autologous stem cell transplant for severe refractory Crohn's disease: The UK experience. BONE MARROW TRANSPLANTATION, 43, S275-S275.
Sorour Y, Dalley C, Snowden JA, Cross NCP & Reilly JT (2009) A novel resistant FIP1L1-PDGFRa mutation in acute myeloid leukaemia, resistance to imatinib mesylate and allogeneic haemopoietic stem cell transplantation. BONE MARROW TRANSPLANTATION, 43, S96-S97.
Krishna R, Day V, Snowden JA, Pawson D, Birchall C, El-Ghariani K, Cook G & Lubenko A (2009) Immediate plasma removal and cryopreservation in HAS/DMSO corrects reduced CD34+cell viability in cryopreserved cell harvests from patients with systemic amyloidosis. BONE MARROW TRANSPLANTATION, 43, S107-S107.
Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD, Evans HR, Snowden JA, Stover DR, Vanderkerken K & Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.. J Bone Miner Res, 24(3), 425-436.
Martin-Rendon E, Snowden JA & Watt SM (2009) Stem cell-related therapies for vascular diseases. Transfusion Medicine, 19(4), 159-171.
Sorour Y, Dalley CD, Snowden JA, Cross NCP & Reilly JT (2009) Acute myeloid leukaemia with associated eosinophilia: Justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene: Correspondence. British Journal of Haematology, 146(2), 225-227.
Snowden JA, Martin-Rendon E & Watt SM (2009) Clinical stem cell therapies for severe autoimmune diseases. Transfusion Medicine, 19(5), 223-234.
Krishna R, Sorour Y, Goepel JR, Kirkbride P, Smith DJ, Ezaydi Y, Dalley CD & Snowden JA (2008) Histopathological Response of Transitional Cell Carcinoma to Arsenic Trioxide during the Treatment of Concurrently Diagnosed Acute Promyelocytic Leukaemia. CLINICAL ONCOLOGY, 20(10), 769-771.
Snowden JA, Kapoor S & Wilson AG (2008) Stem cell transplantation in rheumatoid arthritis.. Autoimmunity, 41(8), 625-631.
Sorour Y, Webber SJ, Wright JG, Morley NJ, Reilly JT, Dalley CD & Snowden JA (2008) Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival. Blood, 112(11), 2391-2391.
Sorour Y, Webber SJ, Wright JG, Morley NJ, Reilly JT, Dalley CD & Snowden JA (2008) Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival. BLOOD, 112(11), 833-834.
Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, Coleman R, Hancock B, Snowden J, Greenfield D & Late Effects Group Sheffield (2008) Ovarian failure following cancer treatment: current management and quality of life.. Hum Reprod, 23(11), 2506-2512.
Cutting R, Dalley C, Ezaydi Y, Winfield D & Snowden JA (2008) Lessons from a Jehovah's Witness with 5q- syndrome: Role of systemic immunosuppression and kinetics of recovery with lenalidomide from a life threatening anaemia. British Journal of Haematology, 142(3), 486-487.
Cutting RJ, Welch E, Channer J, Ezaydi Y, Talley P, Reilly JT & Snowden JA (2008) Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: Failure of a lasting response to a second allogeneic transplant from the original donor. Bone Marrow Transplantation, 42(9), 631-633.
Morris ES, Darbyshire P, Fairlie F, Dalley CD & Snowden JA (2008) Two natural pregnancies following allogeneic transplantation for Fanconi anaemia [1]. British Journal of Haematology, 140(1), 113.
Chakraverty R, Manji N, Clark R, Crawley C, Johnson P, Liakopoulou E, Marsh J, Milligan D, Morris E, Peggs K , Thomson K et al (2007) Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.. Blood, 110(11), 1055-1055.
Craddock CF, Tauro S, Gregory JE, Buckley L, Ward J, Kottaridis P, Thelouli E, Thomson K, Milligan D, Das-Gupta E , Liakpopoulou E et al (2007) Factors Predicting Long Term Survival after Reduced Intensity Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.. Blood, 110(11), 326-326.
Morris ES, Sharrack B, Dalley CD & Snowden JA (2007) The Uhthoff phenomenon: a potential post transplant complication in advanced progressive multiple sclerosis.. Bone Marrow Transplant, 40(10), 1003-1004.
Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R, Davies HA, Snowden JA, Derogatis L, Shalet SM & Ross RJM (2007) Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study.. J Clin Endocrinol Metab, 92(9), 3476-3482.
Kapoor S, Wilson AG, Sharrack B, Lobo A, Akil M, Sun L, Dalley CD & Snowden JA (2007) Haemopoietic stem cell transplantation--an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology.. Hematology, 12(3), 179-191.
Eiser C, Absolom K, Greenfield D, Snowden J, Coleman R, Hancock B, Davies H & Late Effects Group, Sheffield (LEGS) (2007) Follow-up care for young adult survivors of cancer: lessons from pediatrics.. J Cancer Surviv, 1(1), 75-86.
Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K & Johnson RJ (2007) Thalidomide maintenance following high-dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. British Journal of Haematology, 139(3), 429-433.
Chantry AD, Snowden JA, Craddock C, Peggs K, Roddie C, Craig JIO, Orchard K, Towlson KE, Pearce RM, Marks DI & BSBMT Clinical Trials Committee (2006) Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.. Biol Blood Marrow Transplant, 12(12), 1310-1317.
Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T , Fegan C et al (2006) The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. BRIT J HAEMATOL, 134(4), 385-390.
Cutting RJ & Snowden JA (2006) Myeloma in monozygotic twin [2]. British Journal of Haematology, 134(6), 646.
Cutting R, Ezaydi Y, Edbrooke D, El-Ghariani K, Stamps R & Snowden JA (2006) Graft failure and severe autoimmune haemolysis following fludarabine-based reduced-intensity matched unrelated donor bone marrow transplantation for severe aplastic anaemia: Salvage by second transplant with conventional dose conditioning [4]. Bone Marrow Transplantation, 38(4), 317-318.
Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H , Patel DD et al (2006) Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: The evolution from myeloablative to lymphoablative transplant regimens. Arthritis and Rheumatism, 54(12), 3750-3760.
Feyler S, Rawstron A, Jackson G, Snowden J, Hawkins K & Johnson RJ (2005) Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma: A UK Myeloma Forum Phase 2 Study.. Blood, 106(11), 641-641.
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP , Revell P et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. NEW ENGL J MED, 353(1), 33-45.
Hough RE, Snowden JA & Wulffraat NM (2005) Haemopoietic stem cell transplantation in autoimmune diseases: A European perspective. British Journal of Haematology, 128(4), 432-459.
Gratwohl A, Passweg J, Bocelli-Tyndall C, Fassas A, van Laar JM, Farge D, Andolina M, Arnold R, Carreras E, Finke J , Kötter I et al (2005) Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplantation, 35(9), 869-879.
Ponchel F, Verburg RJ, Bingham SJ, Brown AK, Moore J, Protheroe A, Short K, Lawson CA, Morgan AW, Quinn M , Buch M et al (2005) Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.. Arthritis Res Ther, 7(1), R80-R92. View this article in WRRO
Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar JM, Verburg R, Szer J, Taylor K, Joske D , Rule S et al (2004) Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR. J RHEUMATOL, 31(3), 482-488.
Burt RK, Kallunian K, Patel D, Thomas J, Yeager A, Traynor A, Heipe F, Arnold R, Marmont A, Collier D , Glatstein E et al (2004) The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total-body irradiation in systemic sclerosis. Bone Marrow Transplantation, 34(9), 745-751.
Gorin NC (2003) Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood, 102(8), 3043-3051.
Burt RK, Marmont A, Arnold R, Heipe F, Firestein GS, Carrier E, Hahn B, Barr W, Oyama Y, Snowden J , Kalunian K et al (2003) Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus.. Bone Marrow Transplant, 32 Suppl 1, S49-S51.
Moore JJ, Snowden J, Pavletic S, Barr W & Burt R (2003) Hematopoietic stem cell transplantation for severe rheumatoid arthritis.. Bone Marrow Transplant, 32 Suppl 1, S53-S56.
van Laar JM & Pavletic SZ (2003) CD34‐selected versus unmanipulated grafts for severe rheumatoid arthritis: Comment on the article by Moore et al. Arthritis & Rheumatism, 48(5), 1463-1464.
Moore J, Milliken S, Ma D, Biggs J, Brooks P & Snowden J (2003) Reply. Arthritis & Rheumatism, 48(5), 1464-1466.
Moore J, Milliken S, Ma D, Biggs J, Brooks P & Snowden J (2003) CD34-selected versus unmanipulated grafts for severe rheumatoid arthritis: comment on the article by Moore et al - Reply. ARTHRITIS AND RHEUMATISM, 48(5), 1464-1466.
Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, Cannell P, Will R, Rule S, Joske D , Langlands B et al (2002) A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. ARTHRITIS RHEUM, 46(9), 2301-2309.
Bingham S, Ponchel F, Veale D, Reece R, Fearon U, Isaacs J, McGonagle D, Snowden J, Morgan G & Emery P (2002) Highly Selected Autologous Stem Cell Transplantation in Severe Rheumatoid Arthritis with Studies of Peripheral Blood Lymphocyte (Pbl) Reconstitution, Synovial Response and Thymic Function. Clinical Science, 103(s47), 33P-33P.
Bingham SJ, Snowden J, Morgan G & Emery P (2002) High dose immunosuppressive therapy and stem cell transplantation in autoimmune and inflammatory diseases.. Int Immunopharmacol, 2(4), 399-414.
Miall F, Rye A, Fraser M, Hunter A & Snowden JA (2002) Human parainfluenza type 4 infection: A case report highlighting pathogenicity and difficulties in rapid diagnosis in the post-transplant setting [1]. Bone Marrow Transplantation, 29(6), 541-542.
Bingham S, Veale D, Fearon U, Isaacs JD, Morgan G, Emery P, McGonagle D, Reece R, Clague R & Snowden JA (2002) High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis and Rheumatism, 46(3), 837-839.
Snowden J (2001) High dose therapy and autologous hemopoietic stem cell transplantation in rheumatoid arthritis--the feasibility of phase III trials.. J Rheumatol Suppl, 64, 55-59.
Bingham SJ, Snowden J, McGonagle D, Richards S, Isaacs J, Morgan G & Emery P (2001) Autologous stem cell transplantation for rheumatoid arthritis--interim report of 6 patients.. J Rheumatol Suppl, 64, 21-24.
Kashyap A & Snowden J (2001) Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.. J Rheumatol Suppl, 64, 39-41.
Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM, Nash RA, Dunbar CE, Arnold R, Prentice G , Bingham S et al (2001) Collection of hematopoietic stem cells from patients with autoimmune diseases.. Bone Marrow Transplant, 28(1), 1-12.
Bingham S, Veale D, Reece R, Fearon U, Isaacs J, McGonagle D, Snowden J, Morgan G & Emery P (2001) Long-term follow-up of highly selected autologous stem cell transplantation in severe rheumatoid arthritis with studies of synovial response and peripheral blood lymphocyte (PBL) reconstitution. RHEUMATOLOGY, 40, 83-83.
Bingham S, Griffiths B, McGonagle D, Snowden JA, Morgan G & Emery P (2001) Autologous stem cell transplantation for rapidly progressive Jo-1-positive polymyositis with long-term follow-up [2]. British Journal of Haematology, 113(3), 840-841.
Snowden JA (2000) Haemopoetic Stem Cell Transplantation in Autoimmune Diseases, with Special Reference to Rheumatoid Arthritis. Japanese Journal of Clinical Immunology, 23(6), 490-493.
Snowden JA & Brooks PM (2000) Risk taking in patients with rheumatoid arthritis: are the risks of haemopoietic stem cell transplantation acceptable? Reply. RHEUMATOLOGY, 39(6), 681-682.
Hawkey CJ, Snowden JA, Lobo A, Beglinger C & Tyndall A (2000) Stem cell transplantation for inflammatory bowel disease: practical and ethical issues. GUT, 46(6), 869-872.
Mainwaring CJ, Walewska R, Snowden J, Winfield DA, Ng JP, Chan-Lam D, Nolan B, Booker DJ, Stamps R & Sokol RJ (2000) Fatal cold anti-i autoimmune haemolytic anaemia complicating hairy cell leukaemia.. Br J Haematol, 109(3), 641-643.
Snowden JA (2000) Special Lectures on the Pathogenesis and the Pathogenesis-based Treatment of Rheumatoid Arthritis. Haemopoetic stem cell transplantation in autoimmune diseases, with special reference to rheumatoid arthritis.. Japanese Journal of Clinical Immunology, 23(4), 257-260.
Snowden JA, Nivison-Smith I, Atkinson K, Fay K, Concannon A, Dodds A, Milliken S & Biggs J (2000) Allogeneic PBPC transplantation: An effect on incidence and distribution of chronic graft-versus-host disease without long-term survival benefit?. Bone Marrow Transplantation, 25(1), 119-120.
Bingham SJ, Snowden JA & Emery P (2000) Autologous blood stem cell transplantation as therapy for autoimmune diseases. Annals of Medicine, 32(9), 615-621.
Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E & Hart DNJ (2000) Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplantation, 26(3), 309-313.
Snowden JA, Biggs JC, Milliken ST, Fuller A & Brooks PM (1999) A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis and Rheumatism, 42(11), 2286-2292.
Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M, Brooks P, Black C, Durez P, Finke J, Forman S , Fouillard L et al (1999) Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease.. Bone Marrow Transplant, 24(7), 729-734.
Moore J, Snowden J, Milliken S, Cannell P, Szer J, Joske D, Brooks P & Biggs J (1999) PBCST for rheumatoid arthritis - An Australian experience.. EXPERIMENTAL HEMATOLOGY, 27(7), 132-132.
Snowden JA, Nivison-Smith I, Biggs JC & Brooks PM (1999) Risk taking in patients with rheumatoid arthritis: Are the risks of haemopoietic stem cell transplantation acceptable?. Rheumatology, 38(4), 321-324.
Snowden JA, Chan-Lam D, Thomas SE & Ng J-P (1999) Oral or parenteral therapy for vitamin B12 deficiency. The Lancet, 353(9150), 411-411.
Snowden JA & Brooks PM (1999) Hematopoietic stem cell transplantation in rheumatic diseases. Current Opinion in Rheumatology, 11(3), 167-172.
Freeman AG (1999) Oral or parenteral therapy for vitamin B12 deficiency. The Lancet, 353(9150), 410-411.
Snowden JA (1998) Hematopoietic stem cell transplantation in Crohn's disease. GASTROENTEROLOGY, 115(4), 1035-1036.
Brooks PM, Snowden J, Biggs J & Millikin S (1998) A pilot dose escalation of high dose cyclophosphamide (CY) and autologous stem cell therapy (ASCT) in active rheumatoid arthritis (RA).. ARTHRITIS AND RHEUMATISM, 41(9), S132-S132.
Snowden JA, Milliken ST, Brooks PM & Biggs JC (1998) Autografting in severe active rheumatoid arthritis (RA) - Mobilisation and dose escalation studies. BRITISH JOURNAL OF HAEMATOLOGY, 101, 70-70.
Snowden JA, Brooks PM, Milliken ST, Fuller A, Passuello F, Renwick J & Biggs JC (1998) Haemopoietic stem cell (HSC) mobilisation with filgrastim in severe active rheumatoid arthritis (RA). BONE MARROW TRANSPLANTATION, 21, S51-S51.
Snowden JA, Milliken ST, Brooks PM & Biggs JC (1998) High dose cyclophosphamide (Cy) with autologous stem cell rescue in severe active rheumatoid arthritis (RA) - A dose escalation study. BONE MARROW TRANSPLANTATION, 21, S52-S52.
Snowden JA, Kearney P, Kearney A, Cooley HM, Grigg A, Jacobs P, Bergman J, Brooks PM & Biggs JC (1998) Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis and Rheumatism, 41(3), 453-459.
Snowden JA, Biggs JC, Milliken ST, Fuller A, Staniforth D, Passuello F, Renwick J & Brooks PM (1998) A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplantation, 22(11), 1035-1041.
Snowden JA, Nink V, Cooley M, Zaunders J, Keir M, Wright L, Milliken ST, Brooks PM & Biggs JC (1998) Composition and function of peripheral blood stem and progenitor cell harvests from patients with severe active rheumatoid arthritis. British Journal of Haematology, 103(3), 601-609.
Biggs JC, Snowden JA, Milliken ST & Brooks P (1997) Haemopoietic stem cell transplantation (HSCT) for rheumatoid arthritis (RA). Experimental Hematology, 25(8), 902.
Cooley HM, Snowden JA, Grigg AP & Wicks IP (1997) Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis & Rheumatism, 40(9), 1712-1715.
Brooks P, Snowden JA, Fuller A, Milliken S, Biggs JC & Passuello F (1997) A randomised, blinded, placebo controlled, pilot phase 1 study of the tolerability of filgrastim in patients with severe active rheumatoid arthritis for the mobilisation of peripheral blood progenitor cells.. ARTHRITIS AND RHEUMATISM, 40(9), 131-131.
Biggs JC, Snowden JA, Milliken ST & Brooks P (1997) Haemopoietic stem cell transplantation (HSCT) for rheumatoid arthritis (RA). EXPERIMENTAL HEMATOLOGY, 25(8), 611-611.
Snowden JA, Atkinson K, Kearney P, Brooks P & Biggs JC (1997) Allogeneic bone marrow transplantation from a donor with severe active rheumatoid arthritis not resulting in adoptive transfer of disease to recipient. Bone Marrow Transplantation, 20(1), 71-73.
Snowden JA, Patton WN, O'Donnell JL, Hannah EE & Hart DNJ (1997) Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 19(12), 1247-1250.
Snowden JA, Poole J, Bates AJ, Faulkner M, Day V, Booker D, Sokol RJ & Reilly JT (1997) The Rhnull phenotype in an English individual: haematological, serological and immunological studies.. Clin Lab Haematol, 19(2), 143-148.
Snowden JA, Brooks PM & Biggs JC (1997) Haemopoietic stem cell transplantation for autoimmune diseases. British Journal of Haematology, 99(1), 9-22.
Snowden JA & Heaton DC (1997) Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: Further evidence for adoptive autoimmunity. British Journal of Dermatology, 137(1), 130-132.
Snowden JA, Hutchings M, Spearing R & Patton WN (1997) Acquired high titre factor VIII inhibitor with underlying polyarteritis nodosa. Pathology, 29(2), 221-223.
Snowden JA, Angel CA, Winfield DA, Pringle JH & West KP (1997) Angiotropic lymphoma: Report of a case with histiocytic features. Journal of Clinical Pathology, 50(1), 67-70.
Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A & Potter A (1997) Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. British Journal of Haematology, 98(1), 96-102.
Hill G, McClean D, Fraser R, Hart D, Crozier I, Snowden J & Gibbons S (1996) Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia.. Aust N Z J Med, 26(6), 852-853.
Snowden JA, Biggs JC & Brooks PM (1996) Autologous blood stem cell transplantation for autoimmune diseases. Lancet, 348(9035), 1112-1113.
Dapling RB, Snowden JA, West J, Talbot JF, Nelson ME & Greaves M (1996) The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography. Clinical and Laboratory Haematology, 18(4), 277-279.
SNOWDEN JA & GREAVES M (1995) IgA lambda myeloma presenting concurrently in identical twins with subsequent transformation to ‘aggressive phase’ in one. Clinical & Laboratory Haematology, 17(1), 95-96.
WEIR NU, SNOWDEN JA, GREAVES M & DAVIES‐JONES GAB (1995) Livedo reticularis associated with hereditary protein C deficiency and recurrent thromboembolism. British Journal of Dermatology, 132(2), 283-285.
SNOWDEN JA, LAIDLAW ST, CHAMPION AE & REILLY JT (1994) ACUTE PROMYELOCYTIC LEUKEMIA AFTER TREATMENT FOR SEMINOMA WITH CARBOPLATIN. LANCET, 344(8933), 1361-1361.
SNOWDEN JA, WRIGHT JG, PEEL J & WINFIELD DA (1994) BONE-MARROW TRANSPLANTS FROM PERIPHERAL-BLOOD. BRITISH MEDICAL JOURNAL, 309(6955), 671-671.
SNOWDEN JA, FORSTER DMC & MCKENDRICK MW (1994) RECURRENT MIGRAINELIKE SYMPTOMS AND HEMIPLEGIA PRECIPITATED BY FEVER AND ASSOCIATED WITH AN UNDERLYING CEREBRAL ARTERIOVENOUS MALFORMATION. CLINICAL INFECTIOUS DISEASES, 19(3), 547-548.
Jones JW, Pether JVS, Frost RWP, Snowden JA & Ali-Wali WI (1994) Human parvovirus B19: Hard to differentiate from infectious mononucleosis. BMJ, 308(6928), 595-595.
SNOWDEN JA & ALIWALI WI (1994) HUMAN PARVOVIRUS B19 - VIRUS TRANSMISSIBLE IN BLOOD PRODUCTS. BRITISH MEDICAL JOURNAL, 308(6928), 595-595.
Snowden JA, Young MJ & McKendrick MW (1994) Dilatation of the colon complicating acute self-limited colitis.. QJM, 87(1), 55-62.
Wodziński MA, Snowden JA & Reilly JT (1994) Toxic megacolon complicating chemotherapy for acute myeloid leukaemia. Postgraduate Medical Journal, 70(830), 921-923.
Snowden JA, Greaves M & Page K (1994) Reversal of diabetes associated with escape of myeloma: Evidence for inappropriate IGF-II secretion. British Journal of Haematology, 87(1), 202-204.
Snowden JA, Young MJ & Mc Kendrick MW (1994) Dilation of the colon complicating acute self-limited colitis. QJM, 87(1), 55-62.
Snowden JA, Milford-Ward A & Reilly JT (1994) Symptomatic IgG3 deficiency successfully treated with intravenous immunoglobulin therapy. Postgraduate Medical Journal, 70(830), 924-926.
LAIDLAW ST, SNOWDEN JA & BROWN MJ (1993) APLASTIC-ANEMIA AND REMOXIPRIDE. LANCET, 342(8881), 1245-1245.
PHILPOTT N (1993) Aplastic anaemia and remoxipride. The Lancet, 342(8881), 1244-1245.
Mcdonagh AJ, Snowden JA, Stierle C, Elliott K & Messenger AG (1993) HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: the role of cytokines.. Br J Dermatol, 129(3), 250-256.
Snowden JA, Milford-Ward A, Cookson LJ & McKendrick MW (1993) Recurrent lymphocytic meningitis associated with hereditary isolated IgG subclass 3 deficiency. Journal of Infection, 27(3), 285-289.
SNOWDEN JA & MCKENDRICK MW (1992) TOXIC DILATATION AND INFECTIVE DIARRHEA. BRITISH MEDICAL JOURNAL, 305(6848), 314-314.
Snowden J, Harkin P, Thornton J & Wells M (1989) Morphometric assessment of ovarian stromal proliferation. A clinicopathological study Histopathology 14/1 (369–379)/1989. Maturitas, 11(4), 348.
Snowden JA, Bradbury K, Thornton JG & Wells M (1989) Effect of pituitary gonadotrophins on proliferation of primary cultures of human ovarian stroma.. J Pathol, 159(1), 59-65.
Snowden JA, Harkin PJ, Thornton JG & Wells M (1989) Morphometric assessment of ovarian stromal proliferation--a clinicopathological study.. Histopathology, 14(4), 369-379.
Passweg JR, Baldomero H, Alexander T, Angelucci E, Averbuch D, Bazarbachi A, Ciceri F, Raffaella G, Hazenberg MD, Kalwak K , McLornan DP et al () Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT. Bone Marrow Transplantation.
Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I, Lindsey BB, Kearns P, Barnes E, Goodyear CS , Richter A et al () Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. British Journal of Haematology.
Sweeney K, Niblock A, Greenfield D & Snowden J () Immediate improvement in patient care: Auditing adherence to the British Society for Haematology guidelines on screening and management of the long‐term consequences of multiple myeloma and treatment. eJHaem.
Garderet L, Gras L, Koster L, Baaij L, Hamad N, Dsouza A, Estrada‐Merly N, Hari P, Saber W, Cowan AJ , Iida M et al () Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT). American Journal of Hematology.
Ismail A, Nitti R, Sharrack B, Badoglio M, Ambron P, Labopin M, Alexander T, Snowden JA & Greco R () ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP). Bone Marrow Transplantation.
Styczynski J, Tridello G, Knelange N, Wendel L, Ljungman P, Mikulska M, Gil L, Cesaro S, Averbuch D, von dem Borne P , Xhaard A et al () Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation.
Kelleher P, Greathead L, Whitby L, Brando B, Barnett D, Bloxham D, deTute R, Dunlop A, Farren T, Francis S , Payne D et al () European flow cytometry quality assurance guidelines for the diagnosis of primary immune deficiencies and assessment of immune reconstitution following B cell depletion therapies and transplantation. Cytometry Part B: Clinical Cytometry.
Schoemans H, Burns LJ, Liptrott SJ, Murray J, Kenyon M, Barata A, Bolaños N, Scholl I, Hamilton B, Phelan R , Buchbinder D et al () Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party. Bone Marrow Transplantation.
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, von dem Borne P, Snowden JA , Robinson S et al () Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation.
Wright J & Snowden JA () Life Blood: Stories of Leukaemia Patients and their Doctor by Professor DavidMarks, Austin Macauley Publishers, 2024. pp. 177. ISBN: 978‐1‐0358336‐8‐9. British Journal of Haematology.
Scheid C, Eikema D-J, Van Gelder M, Salmenniemi U, Maertens J, Passweg JR, Blaise D, Byrne JL, Kroeger N, Sockel K , Chevallier P et al () Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?. Blood Journal.
Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG , Bonfim C et al () Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica.
Miller LJ, Halliday V, Snowden JA, Aithal GP, Lee J & Greenfield DM () Health professional attitudes and perceptions of prehabilitation and nutrition before haematopoietic cell transplantation. Journal of Human Nutrition and Dietetics.
Bacigalupo A, Bonifazi F, Ciceri F, Gluckman E, Greco R, Nozzoli C, Lombardini L, Martino M, Rambaldi A, Rocha V , Ruggeri A et al () OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024). Bone Marrow Transplantation.
Garderet L, Gras L, Koster L, De Wreede L, Montserrat R, Vincent L, Fenk R, Karunanithi K, Deeren D, Kaufmann M , Kuball J et al () Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Haematologica.
Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman MS, Atkins H, Krasulova E, Kubala Havrdova E , Trneny M et al () Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry.
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, von dem Borne P, Snowden JA , Robinson S et al () Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation.
Montague-Hellen K, Snowden JA, Nield A & Greenfield DM () Patient concerns after haematopoietic stem cell transplantation: an evaluation. Cancer Nursing Practice.
Gurnari C, Koster L, Baaij LGA, Heiblig M, Yakoub-Agha I, Collin M, Passweg JR, BULABOIS C-E, Khan AB, Loschi M , Carnevale-Schianca F et al () Allogeneic Hematopoietic Cell Transplantation for VEXAS Syndrome: Results of a Multicenter Study of the EBMT. Blood Advances.
de Tute RM, Cook G, Cairns DA, Brown JM, Cavenagh J, Ashcroft AJ, Snowden JA, Yong K, Tholouli E, Jenner M , Hockaday A et al () Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial. Bone Marrow Transplantation.
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL , Ciceri F et al () Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nature Medicine.
Moore J, Milliken S, Dodds A, Ma D & Snowden J () James Crawford Biggs 1931–2023. Bone Marrow Transplantation.
Duque-Afonso J, Finke J, Ngoya M, Galimard J-E, Craddock C, Raj K, Bloor A, Nicholson E, Eder M, Kim O , Valerius T et al () Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation.
von Asmuth EGJ, Putter H, Mohseny AB, Schilham MW, Snowden JA, Saccardi R & Lankester AC () Automating outcome analysis after stem cell transplantation: The YORT tool. Bone Marrow Transplantation.
Beksac M, Iacobelli S, Koster L, Cornelissen J, Griskevicius L, Rabin NK, Stoppa AM, Meijer E, Mear J-B, Zeerleder S , Mayer J et al () An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT. Bone Marrow Transplantation.
Styczynski J, Tridello G, Koster L, Knelange N, Wendel L, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C , Ljungman P et al () Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT. Bone Marrow Transplantation.
Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G , Kinsella F et al () Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT. American Journal of Hematology.
Brittain G, Coles AJ, Giovannoni G, Muraro PA, Palace J, Petrie J, Roldan E, Scolding NJ, Snowden JA & Sharrack B () Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?. Practical Neurology.
Penny HA, Rej A, Baggus EMR, Coleman SH, Ward R, Wild G, Bouma G, Trott N, Snowden JA, Wright J , Cross SS et al () Non-Responsive and Refractory Coeliac Disease: Experience from the NHS England National Centre. Nutrients, 14(13), 2776-2776.
Basak G, Peczynski C, Koenecke C, Terwel S, Cabrerizo Y, Penack O, Moiseev I, Schoemans H, Fegueux N, Potter V , Zeerleder S et al () P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION. HemaSphere, 6, 1327-1328.
Sharrack B, Petrie J, Coles A & Snowden JA () Is stem cell transplantation safe and effective in multiple sclerosis?. BMJ, e061514-e061514.
Ruggeri A, De Wreede LC, Müller CR, Crivello P, Bonneville EF, Petersdorf EW, Socié G, Dubois V, Niittyvuopio R, Peräsaari J , Yakoub-Agha I et al () Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation. Haematologica, 108(2), 645-652.
Hernández-Boluda J-C, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M , Saccardi R et al () Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation.
Putter H, Eikema D-J, de Wreede LC, McGrath E, Sánchez-Ortega I, Saccardi R, Snowden JA & van Zwet EW () Benchmarking survival outcomes: A funnel plot for survival data. Statistical Methods in Medical Research, 096228022210841-096228022210841.
Hernández-Boluda J-C, Pereira A, Zinger N, Gras L, Martino R, Paneesha S, Finke J, Chinea A, Rambaldi A, Robin M , Saccardi R et al () Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation.
Czerw T, Iacobelli S, Malpassuti V, Koster L, Kröger N, Robin M, Maertens J, Chevallier P, Watz E, Poiré X , Snowden JA et al () Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation.
Hough RE, Lopes A, Patrick P, Russell NH, Raj K, Tholouli E, Snowden JA, Collin M, El-Mahidi N, Lawrie A , Clifton-Hadley L et al () Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation. Blood Advances.
Snowden JA, Styczyński J, Snarski E & Greco R () Hematopoietic stem cell transplantation in autoimmune diseases: update from EBMT Autoimmune Diseases Working Party with special reference to Poland. Acta Haematologica Polonica, 52(4), 217-224.
Greenfield DM, Salooja N, Peczynski C, van der Werf S, Schoemans H, Hill K, Cortelezzi A, Lupo-Stangellini M, Özkurt ZN, Arat M , Metzner B et al () Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. Bone Marrow Transplantation.
Burt RK, Tappenden P, Balabanov R, Han X, Quigley K, Snowden JA & Sharrack B () The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP. Frontiers in Neurology, 12.
Bazarbachi AH, Al Hamed R, Labopin M, Halaburda K, Labussiere H, Bernasconi P, Schroyens W, Gandemer V, Schaap NPM, Loschi M , Jindra P et al () Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation.
Das J, Sharrack B & Snowden JA () Autologous Hematopoietic Stem Cell Transplantation in Neurological Disorders: Current Approach and Future Directions. Expert Review of Neurotherapeutics.
Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M , Montoto S et al () Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation.
Soto JR, Anthias C, Madrigal A & Snowden JA () Insights Into the Role of Vitamin D as a Biomarker in Stem Cell Transplantation. Frontiers in Immunology, 11.
Laurent C, Marjanovic Z, Ricard L, Henes J, Dulery R, Badoglio M, Farge D, Snowden JA, Moraes D, Dias J , Mohty M et al () Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation.
Anthias C, Apperley J, Bloor A, Byrne J, Collin M, Crawley C, Craddock C, Finnegan D, Gilleece M, Gribben J , Hunter A et al () Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. Bone Marrow Transplantation.
Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, Alexander T, Kirgizov K, Rovira M, Saif M , Saccardi R et al () Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Frontiers in Immunology, 11.
Mankarious M, Matthews NC, Snowden JA & Alfred A () Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD). Frontiers in Immunology, 11.
Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, Daikeler T, Schmalzing M, Schroers R, Martin T , Pugnet G et al () Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica, haematol.2019.230128-haematol.2019.230128.
Kinsella FAM, Bencito A, Kulik D, Hurst E, Gilleece M, Snowden JA, Malladi R, Scarisbrick J, Gennery A & Alfred A () UK national audit of extracorporeal photopheresis (ECP) in chronic graft versus host disease. Leukemia & Lymphoma, 1-4.
Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Saccardi R , Lankester A et al () Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Frontiers in Immunology, 10.
Greenfield D, Blewitt A, Coleman R, Walsh J, Snowden J, Ross R & Han T () Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Endocrine Abstracts.
Lawson MA, Paton-Hough JM, Evans HR, Walker RE, Harris W, Ratnabalan D, Snowden JA & Chantry AD () NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLOS ONE, 10(3), e0119546-e0119546. View this article in WRRO
Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K , Labopin M et al () Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases : updated guidelines and recommendations from the EBMT autoimmune diseases working party (ADWP) and the joint accreditation committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation. View this article in WRRO
Kelsey P, Pearce R, Perry J, Kirkland K, Paul R, Lambert J, Peniket A, Malladi R, Snowden JA & Morley N () Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma—a retrospective study from the BSBMT (BEAM versus LEAM). Bone Marrow Transplantation.

Chapters

Galvan ER, Snowden JA & Greenfield DM (2024) Cardiovascular Diseases and Metabolic Syndrome, The EBMT Handbook (pp. 495-500). Springer International Publishing
Alexander T, Sharrack B, Rovira M, Saccardi R, Farge D, Snowden JA & Greco R (2024) Autoimmune Disease, The EBMT Handbook (pp. 825-836). Springer International Publishing
Saccardi R, Rintala T, McGrath E & Snowden JA (2024) JACIE Accreditation of HCT Programs, The EBMT Handbook (pp. 41-47). Springer International Publishing
Snowden J & Duarte RF (2022) Patient Referral, The EBMT/EHA CAR-T Cell Handbook (pp. 225-227). Springer International Publishing
Hayden P, Gagelmann N & Snowden J (2022) Long-Term Follow-Up and Late Effects, The EBMT/EHA CAR-T Cell Handbook (pp. 183-187). Springer International Publishing
Ros-Soto J, Burt RK & Snowden JA (2021) Allogeneic HSCT and Graft Versus Host Disease (GvHD), Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 300-309). CRC Press
Snowden JA, Greco R, Badoglio M, Labopin M, Alvelo OFD & Pasquini MC (2021) International Registries Sites/Indications/Activity for Hsct in Autoimmune Diseases, Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 271-281). CRC Press
Salooja N, Burt RK & Snowden JA (2021) Late Toxicity and Supportive Care of Patients Undergoing Hematopoietic Cell Transplantation for Autoimmune Diseases, Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 252-263).
Snowden JA, Ismail A, Burt RK & Jessop H (2021) Early Toxicity and Supportive Care of Hsct for Autoimmune Diseases, Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 241-251).
Burt RK, Farge D, Saccardi R, Quigley K, Han X & Snowden JA (2021) Autologous HSCT Conditioning Regimens for Autoimmune Diseases, Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 204-212).
McGrath E, Schwartz J, Warkentin , Saccardi R & Snowden JA (2021) Quality, Accreditation, and Regulation in Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 103-109). CRC Press
Penglase R, Sandler RD, Moore J & Snowden JA (2021) Hematopoietic Stem Cell Transplantation for Rheumatoid Arthritis, Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 547-556).
Aljurf M, Snowden JA, Hayden P, Orchard KH & McGrath E (2021) Correction to: Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy, Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy (pp. C1-C2). Springer International Publishing
Greenfield DM & Snowden JA (2019) Cardiovascular Diseases and Metabolic Syndrome, The EBMT Handbook (pp. 415-420). Springer International Publishing
Saccardi R, McGrath E & Snowden JA (2019) JACIE Accreditation of HSCT Programs, The EBMT Handbook (pp. 35-40). Springer International Publishing
Snowden JA & Webber S (2014) Haematopoietic Stem Cell Transplantation In Thachil J & Hill Q (Ed.), Haematology in Critical Care- a Practical Handbook Wiley-Blackwell
Snowden JA, Saccardi R & Farge D (2012) Autoimmune Diseases In Apperley J (Ed.), EBMT Handbook European School of Haematology
Snowden JA, Moore J, Pavletic S, Bingham S & Burt R (2004) Haemopoietic stem cell transplantation in severe rheumatoid arthritis – world results In Burt RK & Marmont AM (Ed.), Stem Cell Therapy for Autoimmune Disease
Snowden JA, Steward W, Hunter A & O'Bryne K (2001) Acute intestinal failure – malignancy, chemotherapy and haemopoietic stem cell transplantation, Intestinal failure Wisepress
Snowden JA, Bingham S, Morgan G & Emery P (1999) High dose therapy and blood stem cell transplantation for rheumatoid arthritis. In Emery P (Ed.), Rheumatology Highlights 1998-99 (pp. 42-50). Oxford: Health Press.
Snowden JA & Brooks P (1997) High dose therapy and blood stem cell transplantation for autoimmune diseases. In Emery P (Ed.), Rheumatology Highlights 1997

Conference proceedings papers

Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM , Gilkes A et al (2024) Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. Journal of Clinical Oncology, Vol. 42(10) (pp 1158-1168)
Parrish C, Welsh A, Ashcroft J, Olivier C, Hockaday A, Cavenagh J, Snowden J, Drayson M, De Tute R, Owen R , Yong K et al (2024) Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 24 (pp S37-S38)
Muraro P, Kazmi M, De Matteis E, Brittain G, Nicholas R, Silber E, Mehra V, Gabriel I, Lee J, Pearce R , Malladi R et al (2024) Real-world Effectiveness and Safety of Autologous Haematopoietic Stem Cell Transplantation in MS: the UK Experience in 363 patients treated during 2002-2023. MULTIPLE SCLEROSIS JOURNAL, Vol. 30(3) (pp 20-21)
Brittain G, Ismail A, Hoyle N, Roldan E, Snowden J & Sharrack B (2024) The impact of disease modifying treatment washout periods prior to autologous stem cell transplantation for multiple sclerosis: real-world experience at a large centre. MULTIPLE SCLEROSIS JOURNAL, Vol. 30(3) (pp 1073-1074)
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Massey J, Sutton I, Withers B, Burman J, Torkildsen O , Bo L et al (2024) Effectiveness of autologous haematopoietic stem cell transplantation in comparison with immune-reconstitution therapies in relapsing-remitting MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 30(3) (pp 1193-1196)
Garderet L, Gras L, Koster L, Dsouza A, Parameswaran H, Merly NE, Saber W, Cowan A, Iida M, Okamoto S , Takamatsu H et al (2023) WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION GLOBAL STUDY ON BASELINE CHARACTERISTICS/CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS UNDERGOING ASCT, A STUDY OFF 61,725 PATIENTS. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 479-480)
Barkauskiene R, Pryce A, Pearce R, Snowden JA, Malladi R, Potter V, Lee J, Wilson M, Paglucia A, Anthias C , Pawson R et al (2023) GRAFT CRYOPRESERVATION EFFECTS ON THE OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTS IN PAEDIATRIC POPULATION: A MULTICENTRE UK STUDY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 569-570)
Moore J, Milliken S, Withers B, Massey J, Sutton I, Penglase R, Englert H, Laila G, Handel M, Brooks P , Jabbour A et al (2023) AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES AT ST VINCENTS HOSPITAL, SYDNEY-25 YEARS AND 159 PATIENTS: AN ANALYSIS OF DISEASE SPECIFIC OUTCOMES AND SAFETY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 37-38)
von Asmuth EGJ, Putter H, Mohseny AB, Schilham MW, Snowden JA, Saccardi R & Lankester AC (2023) AUTOMATING OUTCOME ANALYSIS FOR SCT PATIENTS: THE YEARLY OUTCOME REVIEW TOOL. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 666-667)
von Asmuth EGJ, Putter H, Mohseny AB, Schilham MW, Snowden JA, Saccardi R & Lankester AC (2023) AUTOMATING OUTCOME ANALYSIS FOR SCT PATIENTS: THE YEARLY OUTCOME REVIEW TOOL. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 688-688)
Bruno A, Gurnari C, Greco R, Alexander T & Snowden J (2023) TOWARD A CLINICAL PHENOTYPE INSPIRED DIAGNOSIS OF AUTOIMMUNE MANIFESTATIONS IN VEXAS SYNDROME: A GUIDE TO UBA1-TESTING FOR THE GENERALIST. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 344-345)
Mayor NP, Szydlo RM, Sheikh Y, Lee J, Pearce RM, Farrow C, Agapiou M, Rao K, Orchard K, Olavarria E , Marsh SGE et al (2023) THE IMPACT OF PATIENT-REPORTED ETHNICITY ON HAEMATOPOIETIC CELL TRANSPLANT OUTCOME: THE UK EXPERIENCE. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 34-34)
Bug G, Labopin M, Byrne JL, Mielke S, Orchard K, Burns D, Potter V, Blaise D, Robinson S, Snowden J , Yakoub-Agha I et al (2023) ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 58-59)
Garderet L, Gras L, Koster L, Montserrat R, Vincent L, Kobbe G, Pillai S, Deeren D, Kaufmann M, Kuball J , Ozdogu H et al (2023) LONG TERM OUTCOMES FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN DEPOSITION DISEASE: A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 478-478)
Kanellopoulos A, Labopin M, Spyridonidis A, Nikolousis E, Platzbecker U, Blaise D, Sengeloev H, Burns D, Schroeder T, Choi G , Tholouli E et al (2023) NON MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING FOR ALLO-HCT FROM SIBLING OR UNRELATED DONORS IN PATIENTS WITH AML=65YEARS. A STUDY FROM THE EBMT ALWP. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 155-156)
Greco R, Snowden JA, Knelange NS, Tridello G, Cacciatore C, Xhaard A, Ciceri F, Collin M, Ferra C, De Becker A , Averbuch D et al (2023) OUTCOME OF SARS-COV2 INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS FOR AUTOIMMUNE DISEASES. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 38-39)
Garderet L, Gras L, Koster L, Dsouza A, Merly NE, Parameswaran H, Saber W, Cowan A, Iida M, Okamoto S , Takamatsu H et al (2023) INTERNATIONAL DIFFERENCES IN BASELINE CHARACTERISTICS AND PRACTICE PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 479-479)
Pagliuca S, Kulasekararaj A, Eikema D-J, Piepenbroek B, Iftikhar R, Satti TM, Griffin M, Laurino M, Kupesiz A, Bertrand Y , Fattizzo B et al (2023) CURRENT USE OF ANDROGENS IN BONE MARROW FAILURE DISORDERS: A REPORT FROM THE SEVERE APLASTIC ANEMIA WORKING PARTY (SAAWP) OF THE EBMT. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 36-37)
Hayden P, Eikema D-J, Koster L, Snowden J, Caillot D, van Gorkom G, Griskevicius L, Arcese W, Crawley C, Musso M , Bulabois CE et al (2023) AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILISATION TECHNIQUES, CELL YIELDS AND PRACTICE VARIATION-BYCOUNTRY IN MYELOMA PATIENTS UNDERGOING FIRST AUTOLOGOUS STEM CELL TRANSPLANTS IN EBMT CENTRES (2012-2021). BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 602-603)
Alexander T, Badglio M, Labopin M, Daikeler T, Farge D, Kazmi M, Rovira M, Saccardi R, Snowden J & Greco R (2023) MONITORING AND MANAGEMENT OF CMV AND EBV AFTER AUTOLOGOUS HAEMATOPOIETIC CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES: A SURVEY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP). BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 418-419)
Hewerdine S, Judge G, Lee J, Braund H, Allen H, Snowden JA, Carpenter B, Potter V, Marsh SGE & Mayor NP (2023) COMPLETION OF THE PILOT PROJECT EVALUATING THE BENEFIT OF ADDITIONAL SUPPORT IN HCT RESEARCH DATA MANAGEMENT ON BEHALF OF ANTHONY NOLAN AND BSBMTCT. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 682-683)
Riva E, Kastritis E, Gras L, Koster L, Caillot D, Tucci A, Lanza F, Musso M, Sirvent A, Illes A , Ram R et al (2023) NO EVIDENCE FOR IMPROVED OVERALL SURVIVAL OR PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 70-75 UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION COMPARED TO A NON-TRANSPLANT STRATEGY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 366-367)
Garderet L, Gras L, Koster L, D'Souza A, Estrada-Merly N, Hari P, Saber W, Cowan AJ, Iida M, Okamoto S , Takamatsu H et al (2022) International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation. Blood, Vol. 140(Supplement 1) (pp 5225-5227)
Pagliuca S, Kulasekararaj A, Eikema D-J, Piepenbroek B, Iftikhar R, Satti TM, Griffin M, Laurino M, Kupesiz OA, Bertrand Y , Fattizzo B et al (2022) Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, Vol. 140(Supplement 1) (pp 5799-5800)
Oporto Espuelas M, Burridge S, Bonney D, Watts K, Roddie C, O'Reilly MA, Shenton G, Snowden JA, Furness C, Jalowiec KAA , Neill L et al (2022) Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure. Blood, Vol. 140(Supplement 1) (pp 2408-2410)
Garderet L, Gras L, Koster L, D'Souza A, Estrada-Merly N, Hari P, Saber W, Cowan AJ, Iida M, Okamoto S , Takamatsu H et al (2022) Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers. Blood, Vol. 140(Supplement 1) (pp 4839-4842)
Maniusyte R, Pryce A, Pearce R, Snowden JA, Malladi R, Potter V, Lee J, Wilson M, Pagliuca A, Olavarria E , Palanicawandar R et al (2022) Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes. Blood, Vol. 140(Supplement 1) (pp 7552-7554)
Abamba C, Lee J, Pearce RM, Wilson MC, Paul RE & Snowden JA (2022) Observational trends in GvHD data submissions: Do centres have a data collection process and is this responsible for submission improvements?. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 460-461)
Kirgizov K, Greco R, Badoglio M, Labopin M, Saccardi R, Rovira M, Farge D, Schaap N, Moore J, Polushin A , Finke J et al (2022) Late complications after autologous HSCT for autoimmune diseases: a retrospective study from the EBMT autoimmune. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 25-26)
Garderet L, Grass L, Koster L, D'Souza A, Estrada N, Parameswaran H, Saber W, Cowan A, Iida M, Shin O , Takamatsu H et al (2022) International differences in baseline characteristics and practice patterns in newly diagnosed multiple myeloma (MM) patients undergoing upfront autologous stem cell transplantation. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 44-45)
Murrell J, Hill T, State A, Francis S, Pickersgill L, Raza M & Snowden JA (2022) Impact of societal and healthcare infection control measures on incidence of non-sars-2-cov respiratory viral infections in HSCT in-patient admissions; a single uk centre experience. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 272-273)
Maniusyte R, Pryce A, Pearce R, Snowden JA, Malladi R, Potter V, Lee J, Wilson M, Pawson R & Danby R (2022) Does graft cryopreservation affect the outcomes of allogeneic haematopoietic cell transplants? A UK multicentre case control study during COVID19 pandemic. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 97-97)
Ros-Soto J, Matthews NC, Burton C, Szydlo R, Alfred A, Andrews R, Anthias C, Mehra V, Potter V, Madrigal A & Snowden JA (2022) Association between vitamin d and GVHD biomarkers with response to immunosuppression and survival in acute GVHD: An exploratory study. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 216-216)
Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman M, Atkins H, Horakova D, Havrdova EK , Krasulova E et al (2022) Effectiveness of autologous haematopoietic stem cell transplantation in comparison with natalizumab in progressive MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 953-954)
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R , Grigg A et al (2022) Comparative effectiveness of autologous haematopoietic stem cell transplantation with immune reconstitution therapies in relapsing-remitting MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 619-621)
Kalincik T, Sharman S, Roos I, Freedman M, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R , Grigg A et al (2022) Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 11-14)
Brittain G, Glover R, Roldan E, Papaioannou D, Cooper C, Muraro P, Snowden J & Sharrack B (2022) A changing target - adapting ongoing autologous haematopoietic stem cell transplantation clinical trials to evolving clinical practice in the treatment of highly active relapsing remitting multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 843-843)
Lindsay J, Din S, Hawkey C, Hind D, Irving P, Lobo A, Mahida Y, Moran G, Parkes M, Satsangi J , Subramanian S et al (2021) OFR-9 An RCT of autologous stem-cell transplantation in treatment refractory Crohn’s disease (low-intensity therapy evaluation): ASTIClite. Oral
Dillon J, Hayden PJ, Eikema D-J, Koster L, Blaise D, Nicholson E, Potter V, Rabin N, Byrne J, Cornelissen J , Chevallier P et al (2021) Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 327-328)
Scheid C, Eikema D-J, Niittyvuopio R, Maertens J, Passweg J, Blaise D, Byrne J, Kroeger N, Bornhaeuser M, Chevallier P , Bourhis J-H et al (2021) Change In IPSS-R Between Diagnosis And Transplant And Transplant Outcome in Patients With MDS. A Retrospective Analysis From The Chronic Malignancies Working Party. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 141-142)
Drozd-Sokolowska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G, Pouli A, Crawley C, Wilson KMO, Tilly H , Byrne J et al (2021) Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 133-134)
Schoemans H, Verhoeven B, Bolanos N, Lewis C, Liptrott SJ, Scholl I, Barata A, Johnson P, Buk D, Pretzel D , Van Biezen A et al (2021) One Thousand Voices Address Patient Engagement in Hematopoietic Stem Cell Transplantation And Cell Therapy: Results of A Survey From The EBMT. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 160-162)
Chabannon C, Terwel S, Hoogenboom JD, Basak G, Corbacioglu S, de la Camara R, Dolstra H, Glass B, Greco R, Lankester A , Mohty M et al (2021) Building of The G0-CAR-T Initiative to Promote Use of Data Collected from Patients Treated With CAR-T Cells AT EU OR EBMT Affiliated Programs. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 43-44)
Creasey T, Barretta E, Kirkwood A, Schwab C, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan A, Morley N , Snowden J et al (2020) Genetic and genomic characterisation of older adults with acute lymphoblastic leukemia treated on the UKALL14 and UKALL60+clinical trials. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 189 (pp 58-58)
Jones G, Darby F, Moss R, Vogt K, Skull J, Velikova G, Greenfield D, Bekker H, Mahmoodi N, Snowden J , Yeomanson D et al (2020) Cancer, fertility and me: a NEW fertility preservation patient decision aid to support YOUNG women with breast cancer. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 578-578)
Styczynski J, Tridello G, Knelange N, Veelken JH, Socie G, Mielke S, Neven B, Snowden JA, Dalle J-H, Rubio MT , Crawley C et al (2020) Adenovirus Infections after HCT: Infectious Diseases Working Party Retrospective EBMT Registry Study. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 467-468)
Das J, Gill A, Lo C, Chan-Lam N, Price S, Wharton S, Jessop H, Sharrack B & Snowden J (2020) Multiple sclerosis-like CNS inflammation following allogeneic haematopoietic stem cell transplantation treated with a 'domino' autologous haematopoietic stem cell transplantation. NEUROLOGY, Vol. 94(15)
Morris E, Bigley V, Burns SO, Patel S, Lowe D, Laurence A, Elcombe S, Baxendale H, Uttenthal B, Huissoon A , Sargur R et al (2020) National Health Service England (NHSE) Program for Selection of Adult Primary Immunodeficiency Patients For Allogeneic Haematopoietic Stem Cell Transplantation. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 104-105)
Bell S, Jessop H, Chantry A, Sharrack B & Snowden J (2020) The use of Autologous Haemopoetic Stem Cell Transplantation (aHSCT) in Multiple Sclerosis after Alemtuzumab Treatment Failure: A Case Series. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 227-227)
Saccardi R, Badoglio M, Burman J, Helbig G, Innocenti C, Kazmi M, Mancardi GL, Moore J, Muraro P, Sharrack B , Smilowski M et al (2020) Beam vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 37-38)
Sharrack B, Snowden J & Muraro P (2020) Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (starms). MULTIPLE SCLEROSIS JOURNAL, Vol. 26(3_SUPPL) (pp 209-210)
Sharrack B, Saccardi R, Alexander T, Manuela B, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K , Labopin M et al (2020) Autologous haematopoietic stem cell transplantation in multiple sclerosis and other immune-mediated neurological diseases: guidelines and recommendations of the European Society for Blood and Marrow Transplantation and the Joint Accreditation Committee of the International Society for Cellular Therapy. NEUROLOGY, Vol. 94(15)
Bell S, Snowden J, Jessop H, Das J, Ismail A & Sharrack B (2020) The use of Autologous Haemopoetic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis after Alemtuzumab treatment failure: a case series. NEUROLOGY, Vol. 94(15)
Smith R, Snowden J & Akil M (2020) HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS: SHEFFIELD TEACHING HOSPITALS' EXPERIENCE. RHEUMATOLOGY, Vol. 59
Furness CL, Hough R, Cummins M, Murphy G, Ghorashian S, Amrolia P, Roddie C, O'Reilly M, Wynn R, Bonney D , Marks D et al (2020) National Implementation of the use of Tisagenlecleucel in Paediatric and Young Adult Patients with Acute Lymphoblastic Leukaemia (ALL) in National Health Service England (NHSE). BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 228-229)
Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, Alexander T, Kirgizov K, Rovira M, Saif M , Saccardi R et al (2020) Diagnosis and Management of Secondary HLH/MAS following HSCT and CAR-t Cell Therapy in Adults; An EBMT-wide Survey on Behalf of the ADWP and TCWP. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 582-583)
Puyade M, Patel A, Lim YL, Blank N, Badoglio M, Gualandi F, Ma D, Maximova N, Alexander T & Snowden J (2020) Autologous Stem Cell Transplantation in Behcet ' s Disease: A Retrospective Study. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 224-225)
Devillier R, Eikema D-J, Bosman P, Dufour C, Aljurf M, Wu D, Maschan A, Afanasyev B, Veelken JH, Collin M , Snowden J et al (2020) GVHD and Relapse Free Survival (GRFS) After Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 34-35)
Laurent C, Marjanovic Z, Ricard L, Henes J, Dulery R, Badoglio M, Farge D, Snowden J, Moraes D, Dias J , Mohty M et al (2020) Outcome of Autologous Hematopoietic Stem Cell Transplantation for Refractory Takayasu Arteritis, A Retrospective Survey from the Autoimmune Diseases Working Party (ADWP) of the Ebmt. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 226-227)
Lum SH, Samarasinghe S, Wynn R, Eikeman D-J, Bosman P, Aksoylar S, Ghavamzadeh A, Bierings M, Bertrand Y, Kitra-Roussou V , Smiers F et al (2020) Outcome of Haematopoietic Cell Transplantation in Children with Fanconi Anaemia: A Study on Behalf of the EBMT SAAWP and PDWP. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 35-36)
Drozd-Sokolowska J, Tridello G, Kozijn AE, Karakukcu M, Ben Abdeljelil N, Kroeger N, Passweg J, Aljurf M, Colita A, Atay D , Tanase A et al (2020) Tuberculosis After Hematopoietic Stem Cell Transplantation: Retrospective Study of Infectious Diseases Working Party EBMT. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 110-112)
Soto JR, Snowden JA, Szydlo R, Nicholson E, Madrigal A, Easdale S, Ethell M, Potter M & Anthias C (2020) Donor Factors Influence Outcomes of Patients Receiving Donor Lymphocyte Infusion for Mixed Chimerism after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 551-551)
Dignan F, Hamblin A, Chong A, Perry J, Kenyon M, Miller P, Gilleece M, Hunter H & Snowden J (2020) Survivorship Care for Allogeneic Transplant Patients in The UK: Current Service Provision and Barriers to Implementation. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 618-619)
Puyade M, Amit P, Lim YJ, Blank N, Badoglio M, Gualandi F, Ma DD, Greco A, Maximova N, Alexander T & Snowden JA (2020) Autologous Hematopoietic Stem Cell Transplantation for Behcet's Disease: A Retrospective Survey of Patients Treated in Europe, on the Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Bone Marrow Transplantation. ARTHRITIS & RHEUMATOLOGY, Vol. 72
Sanichar M, Claire M, Collins N, Roche L, Snowden J, Whittle R & Key T (2020) THE CLINICAL IMPACT OF PERMISSIVE AND NON-PERMISSIVE HLA-DPB1 MISMATCHES IN HAEMOPOIETIC STEM CELL TRANSPLANTATION, A RETROSPECTIVE STUDY. HLA, Vol. 95(4) (pp 394-394)
Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, van der Werf S, Knelange N, Averbuch D, Socie G, Veelken H , Dalle J-H et al (2019) Donor EBV-positive serostatus increases the risk of chronic GVHD in patients with non-malignant hematological disorders: Infectious diseases working party EBMT study. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 400-401)
Greco R, Labopin M, Badoglio M, Veys P, Silva J, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Saccardi R , Lankester A et al (2019) Allogeneic hsct for autoimmune diseases: A retrospective study from the ebmt autoimmune diseases, inborn errors and paediatric working parties. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 33-34)
Cesaro S, Tridello G, Knelange NS, Schaap N, Martin M, Snowden J, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T , Russell NH et al (2019) Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non leukemic patients: An outcome analysis on behalf of IDWP. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 397-399)
Shouval R, Fein JA, Labopin M, Duarte RF, Corbacioglu S, Bader P, Chabannon C, Kuball J, Basak G, de Latour RP , Lankeste A et al (2019) Young HLA-matched unrelated donors are comparable to matched sibling donors in elderly patients receiving reduced-intensity conditioning: an analysis on behalf of the EBMT scientific council. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 602-603)
Burt R, Balabanov R, Snowden J, Sharrack B, Oliveira MC, Nelson F & Burman J (2019) HSCT treatment for multiple sclerosis: Results from the MIST trial. EUROPEAN JOURNAL OF NEUROLOGY, Vol. 26 (pp 978-978)
Sharrack B & Snowden J (2019) Autologous haematopoietic stem cell transplantation for severe treatment resistant autoimmune diseases. HUMAN GENE THERAPY, Vol. 30(8) (pp A5-A5)
Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, Daikeler T, Schmalzing M, Schroers R, Martin T , Pugnet G et al (2019) Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis - Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT). ARTHRITIS & RHEUMATOLOGY, Vol. 71
Greenfield DM, Salooja N, Peczynski C, van der Werf S, Schoemans H, Hill K, Cortelezzi A, Lupo Stanghellini MT, Ozkurt ZN, Arat M , Metzner B et al (2018) Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study. Blood, Vol. 132(Supplement 1) (pp 251-251)
Cook G, Parrish C, Yong K, Cavenagh J, Snowden JA, Drayson MT, Garg M, Cairns D, Ashcroft J, Striha A , Hockaday A et al (2018) Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. Blood, Vol. 132(Supplement 1) (pp 255-255)
Farge D, Snowden JA, Badoglio M, Labopin M, Scherer HU, Del Papa N, Kanz L, Schmalzing M, Martin T, Rovira M , Daikeler T et al (2018) Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP). Blood, Vol. 132(Supplement 1) (pp 3431-3431)
Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied N-J, Foà R, Cornelissen JJ, Lioure B, Potter V , Poire X et al (2018) Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT. Blood, Vol. 132(Supplement 1) (pp 3425-3425)
Das J, Snowden J, Burman J, Freedman M, Atkins H, Bowman M, Burt R, Sarccardi R, Innocenti C, Mistry S , Bell S et al (2018) The use of autologous haematopoietic stem cell transplantation as a first line disease modifying therapy in patients with 'aggressive' multiple sclerosis.. MULTIPLE SCLEROSIS JOURNAL, Vol. 24 (pp 87-88)
Jones GL, Vogt K, Darby F, Mahmoodi N, Hughes J, Greenfield D, Skull J, Lane S, Brauten-Smith G, Yeomanson D , Baskind NE et al (2018) Experience of developing and evaluating a fertility preservation patient decision aid for teenage and adult women with cancer for use in oncology settings, UK (The Cancer, Fertility and Me study). PSYCHO-ONCOLOGY, Vol. 27 (pp 45-45)
Styczynski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P , Averbuch D et al (2018) Lethal infectious complications after hematopoietic stem cell transplantation: progress and challenges in Infectious Diseases Working Party study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 94-95)
Morley N, Snowden J, Pearce R, Perry J, Paul R, Kirkland K, Lambert J, Malladi R & Peniket A (2018) BEAM versus LEAM conditioning chemotherapy for autologous transplantation in lymphoma. A retrospective study from the BSBMT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 258-258)
Raj K, Protheroe R, Smith M, Gilleece M, Snowden JA, Uttenthal B, Irvine D, Collin M, Paneesha S, Salim R , Tholouli E et al (2018) Peripheral blood stem cell RIC haploidentical transplantation low incidence of GVHD and non relapse mortality: Preliminary results from the prospective phase II UK Haplo study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 752-754)
Shouval R, Fein J, Labopin M, Kroger N, Duarte RF, Bader P, Bonini C, Kuball J, Basak G, Dufour C , Lankester A et al (2018) Should Donor Selection be Driven by Disease Risk? A Retrospective Analysis of the EBMT Registry on Behalf of the Acute Leukemia Working Party. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 135-136)
Chalandon Y, Sbianchi G, Hoek J, Apperley J, Itala-Remes M, Markiewicz M, Byrne J, Sengeloev H, Chaudri N, Malladi R , Remenyi P et al (2018) Allogeneic stem cell transplantation in patients with CML-CP in the era of third generation tyrosine kinase inhibitors: a study by the CMWP of the EBMT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 45-46)
Samuelson C, Alexander T, Daikeler T, Badoglio M, Henes J, Akil M, Skagerlind L, Ehninger G, Jantunen E, Farge D & Snowden JA (2018) Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV): Results of a EBMT Retrospective Survey. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 203-204)
Thorpe AE, Kass-Iliyya L, Jessop H, Chantry A, Hadjivassiliou M, Sharrack B & Snowden JA (2018) Autologous Haematopoietic Stem Cell Transplantation (Auto-HSCT) in Stiff Person Syndrome (SPS): The Sheffield Experience. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 204-205)
Das J, Snowden J, Mistry S, Jessop H, Bowman M, Ismail A, Bell S, Freedman M, Atkins H, Burman J & Sharrack B (2018) The use of Autologous Haematopoietic Stem Cell Transplantation in treatment naive patients with severe multiple sclerosis. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 38-39)
Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, Daikeler T, Schmalzing M, Schroers R, Martin T , Pugnet G et al (2018) Autologous Stem cell transplantation for progressive systemic sclerosis: an EBMT Autoimmune Disease Working Party prospective non-interventional approach. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 37-38)
Ward KN, Ljungman P, Hoek J, Finke J, Niederwieser D, Einsele H, Fegueux N, Angel Diaz M, Maria Fernandez J, Menard A-L , Collin M et al (2018) Infectious Diseases Working Party Retrospective Study on HHV-6 encephalitis: clinical characteristics and outcome after allogeneic HSCT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 565-566)
Snowden J, Keen C, Smith L, Skilbeck J, Ross H, Collins K, Simpson S, Dixey J, Walters S, Greenfield D & Mawson S (2018) Is it feasible to conduct a randomised controlled trial of pre-habilitation in multiple myeloma (MM) patients awaiting autologous haematopoietic stem-cell transplantation (AHSCT)? The PREeMPT study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 343-344)
Greenfield D, Snowden J, Morley N, Wright J, Evans C & DeSilva T (2018) Vaccine preventable diseases: a clinical evaluation of antibody reconstitution after autologous HCT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 381-382)
Chalandon Y, Sbianchi G, Hoek J, Apperley J, Itala-Remes M, Markiewicz M, Byrne J, Sengeloev H, Chaudri N, Malladi R , Remenyi P et al (2018) Allogeneic stem cell transplantation in patients with CML-CP in the era of third generation tyrosine kinase inhibitors: a study by the CMWP of the EBMT. SWISS MEDICAL WEEKLY, Vol. 148 (pp 4S-4S)
Alexander T, Samuelson C, Daikeler T, Henes J, Skagerlind L, Akil M, Ehninger G, Jantunen E, Farge D & Snowden J (2018) SAT0549 Autologous hematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) – a ebmt retrospective survey. Saturday, 16 JUNE 2018
Das J, Snowden J, Mistry S, Jessop H, Bell S & Sharrack B (2018) Autologous Haematopoietic Stem Cell Transplantation in Treatment Naive Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 90
Burt RK, Balabanov R, Snowden JA, Sharrack B, Oliveira MC & Burman J (2018) Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial. NEUROLOGY, Vol. 90
Raj K, Protheroe R, Smith M, Gilleece M, Snowden J, Uttenthal B, Irvine D, Collin M, Paneesha S, Salim R , Tholouli E et al (2018) Peripheral blood stem cell RIC haploidentical stem cell transplantation low TRM, low rates of GVHD: Preliminary results from the prospective Phase II single arm UK Haplo study (Bloodwise: 11034). BRITISH JOURNAL OF HAEMATOLOGY, Vol. 181 (pp 13-13)
Brierley C, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J , Onida F et al (2018) Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party. JOURNAL OF CROHNS & COLITIS, Vol. 12 (pp S14-S15)
Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M , Lindsay J et al (2018) ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review. JOURNAL OF CROHNS & COLITIS, Vol. 12 (pp S70-S71)
Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kroeger N, Kuball J, Lanza F , Montoto S et al (2017) Use of haploidentical stem cell transplantation continues to increase, the 2015 European society for blood and marrow transplant activity survey report. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S191-S192)
Brierley C, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J , Onida F et al (2017) Autologous haematopoietic stem cell transplantation (AHSCT) for Crohn's disease (CD): A retrospective study of outcomes from the EBMT autoimmune diseases working party (ADWP). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S418-S418)
Domingo-Domenech E, Boumendil A, Climent F, Sengeloev H, Ljungman P, Wattad M, Arat M, Finel H, Schaap M, Ganser A , Yeshurun M et al (2017) Autologous stem cell transplantation for systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S440-S440)
Shouval R, Fein J, Labopin M, Kroger N, Duarte RF, Bader P, Bonini C, Dreger P, DuFour C, Gennery A , Kuball J et al (2017) Application of the disease risk index for risk stratification of allogeneic hematopoietic stem cell transplantation in a large cohort of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S12-S13)
Kuehl J-S, Snowden J, Aubourg P, Koehler W & Arnold R (2017) HSCT for adult cerebral adrenoleukodystrophy. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S120-S120)
Mapplebeck C, Sharrack B, Kaur H, Ezaydi Y, Jessop H, Pickersgill L, Scott L, Raza M & Snowden JA (2017) EBV and CMV reactivation following autologous haematopoietic stem cell transplantation (HSCT) for autoimmune neurological diseases resolves spontaneously and rarely requires treatment. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S419-S419)
Miller PDE, de Silva T, Leonard H, Goddard K, Anthias C, Hoschler K, Peggs K, Madrigal A & Snowden JA (2017) Viral microneutralization assay to determine seasonal influenza vaccine immunogenicity in the first year post reduced intensity conditioning allogeneic HSCT. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S269-S270)
Greco R, Labopin M, Badoglio M, Veys P, Silva J, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Tobias A , Gennery A et al (2017) Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT autoimmune diseases, inborn errors and paediatric working parties. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S42-S42)
Tappenden P, Wang Y, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D, Sharrack B & Snowden J (2017) Evaluating the cost-effectiveness of autologous haematopoietic stem cell transplantation (aHSCT) versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (MAIC). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S41-S41)
Morley N, Kirkwood A, Moorman A, Clifton-Hadley L, Rowntree C, Wrench B, Marwood E, Patrick P, Snowden J, Rijneveld A , Marks D et al (2017) RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA. HAEMATOLOGICA, Vol. 102 (pp 31-32)
Galleu A, Deplano S, Szydlo R, Milojkovic D, Bradshaw A, Wynn R, Marks D, Richardson D, Orchard K, Kanfer E , Tholouli E et al (2017) MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES. HAEMATOLOGICA, Vol. 102 (pp 336-337)
Ismail A, Hickman S, Paling D, Phelan J, Havercroft J, Webster S, Alexander HJ, Snowden J & Sharrack B (2017) The impact of the BBC Panorama television programme on public awareness of autologous haematopoietic stem cell transplantation (AHSCT) for patients with multiple sclerosis. NEUROLOGY, Vol. 88
Shouval R, Fein J, Labopin M, Kroger N, Duarte RF, Bader P, Bonini C, Dreger P, DuFour C, Gennery A , Kuball J et al (2016) The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). Blood, Vol. 128(22) (pp 988-988)
Olavarria E, Schleuning M, Iacobelli S, Hoek J, Blok H-J, Aljurf M, Afanasyev BV, Volin L, Sengeloev H, Masszi T , Passweg J et al (2016) An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. Blood, Vol. 128(22) (pp 628-628)
Lawless S, Simona I, van Biezen A, Koster L, Chevallier P, Blaise D, Foà R, Tabrizi R, Schaap NPM, Lenhoff S , Russell NH et al (2016) Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. Blood, Vol. 128(22) (pp 2293-2293)
Cook G, Carter CR, Brock K, McQuaker G, Snowden JA, Crawley C, Hunter H, Cavenagh JD, Lobb M, Cullen K , Hodgkinson A et al (2016) Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma. Blood, Vol. 128(22) (pp 4585-4585)
Gagelmann N, Iacobelli S, Koster L, Nahi H, Stoppa A-M, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C , Arcese W et al (2016) Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party. Blood, Vol. 128(22) (pp 2266-2266)
Ismail A, Hickman S, Paling D, Phelan J, Havercroft J, Webster S, Alexander HJ, Snowden J & Sharrack B (2016) The impact of the BBC Panorama television programme on public awareness of autologous haematopoietic stem cell therapy (AHSCT) for patients with multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL, Vol. 22 (pp 784-784)
Morley N, Kirkwood A, Moorman A, Smith P, Rowntree C, Wrench B, Marwood E, Patrick P, Snowden J, Rijneveld A , Marks D et al (2016) INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA. HAEMATOLOGICA, Vol. 101 (pp 34-34)
Bell S, Kelsey P, Jessop H, Snowden J & Sharrack B (2016) The Use of Autologous Haemopoietic Stem Cell Transplantation in Treating Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 86
Bell S, Kelsey P, Jessop H, Snowden J & Sharrack B (2016) The Use of Autologous Haemopoietic Stem Cell Transplantation in Treating Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 86
Mohammed MK, Snowden J, Rosario DJ & Munir M (2016) High dose melphalan and autologous stem cell transplantation following urinary bladder reconstruction with ileum: Measures to minimise mucositis. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 178-178)
Cook G, Williams C, Cairns DA, Hockaday A, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H , Bird JM et al (2016) A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 5-6)
Samuelson CV, Griffin M, Welch E, Went R, Kaul S, Ng JP, Barker H & Snowden JA (2016) Mortality within 30 days of systemic anticancer therapy (SACT) - results of a multi-site audit following the NCEPOD model in the South Yorkshire region. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 34-34)
Ahmedzai SH, Snowden JA, Cox A, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Parrish C, Yong K, Cavet J , Hunter H et al (2016) Balancing therapeutic impact of treatment strategies with quality of life and pain experience in multiple myeloma: New insights into influence of genetic variants. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 132-133)
Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavanagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H , Bird JH et al (2016) Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: Results from the Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 165-165)
Miller PDE, de Silva T, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A , Snowden JA et al (2016) Routine Vaccination Programme (RVP) Practice after Adult and Paediatric Allogeneic Haematopoietic Stem Cell Transplant (HSCT): A British Society of Blood and Marrow Transplantation (BSBMT) Survey of UK NHS-Based Programmes. BONE MARROW TRANSPLANTATION, Vol. 51 (pp S400-S401)
Holbro A, Baldomero H, Buser A, Chabannon C, Lanza F, Snowden J, Worel N, Sureda A, Badoglio M, Passweg J , Bonini C et al (2016) Graft storage and disposal policies in a large group of european centers: a survey by the cellular therapy and immunobiology working party (CTIWP) of the European Group For Blood And Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION, Vol. 51 (pp S50-S51)
Lawless S, Iacobelli S, van Biezen A, Koster L, Chevallier P, Blaise D, Foa R, Tabriz R, Schaap N, Lenhoff S , Russell N et al (2016) Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. BONE MARROW TRANSPLANTATION, Vol. 51 (pp S18-S19)
Veys P, Danby R, Vora A, Slatter M, Wynn R, Lawson S, Steward C, Gibson B, Potter M, de la Fuente J , Shenton G et al (2016) UK experience of unrelated cord blood transplantation in paediatric patients. British Journal of Haematology, Vol. 172(3) (pp 482-486)
Cook G, Williams C, Cairns DA, Hockaday A, Cavenagh J, Snowden JA, Parrish C, Yong KL, Cavet J, Hunter H , Bird J et al (2015) ASCT2A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial. BLOOD, Vol. 126(23)
Samarasinghe S, Iacobelli S, Knol C, Hamladji R-M, Socie G, Aljurf M, Koh M, Sengeloev H, Dalle J-H, Robinson S , Bacigalupo A et al (2015) Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party. Blood, Vol. 126(23) (pp 1210-1210)
Guillaume-Jugnot P, Marjanovic Z, Labopin M, Terriou L, Deligny C, Lioure B, Martin T, Leblond V, Pugnet G, Blaise D , Peffault de Latour R et al (2015) Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity. Blood, Vol. 126(23) (pp 1985-1985)
Ashcroft J, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Snowden JA, Parrish C, Yong KL, Cavet J, Hunter H , Bird J et al (2015) Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial. Blood, Vol. 126(23) (pp 1981-1981)
Ahmedzai SH, Snowden JA, Cox A, Cairns DA, Williams CD, Hockaday A, Cavenagh J, Parrish C, Yong KL, Cavet J , Hunter H et al (2015) Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience. Blood, Vol. 126(23) (pp 3180-3180)
Kelsey P, Bell SM, Jessop H, Snowden JA & Sharrack B (2015) AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANT IN MS: SHEFFIELD COHORT. Journal of Neurology, Neurosurgery & Psychiatry, Vol. 86(11) (pp e4.116-e4)
Snowden J, Badoglio M & Farge D (2015) EBMT Autoimmune Diseases Working Party (ADWP) Database: Activity 1994-2014. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S112-S112)
Greenfield D, Snowden J, Schoemans H, Hill K, Annaloro C, Lupo-Stanghellini MT, Aki Z, Arat M, Metzner B, Turlure P , Han T et al (2015) Metabolic syndrome is common following haematopoietic cell transplantation (HCT) and is associated with increased cardiovascular disease: an EBMT cross-sectional non-interventional study. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S89-S90)
Cesaro S, Tridello G, Volin L, Craddock C, Michallet M, Schaap N, Cornelissen J, Ljungman P, Hunter A, Maertens J , Russell N et al (2015) A retrospective IDWP-ALWP study on Candida infections in allogeneic haematopoietic stem cell transplant patients. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S32-S33)
Collins N, Whittle R, Robertson K, Lunn R, Sills K, Bloor A, Snowden J & Key T (2015) CD34+count and not total nucleated cell count has impact on OS in adult dUCBT. BONE MARROW TRANSPLANTATION, Vol. 50 (pp 5566-5567)
Clay J, Kelsey P, Bell S, Lim C, Helen J, Nicholas R, Silber E, Malik O, Brex P, Muraro P , Sharrack B et al (2015) Autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a UK cohort from two centres. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S61-S61)
Meiring J, De Silva T & Snowden J (2015) A study of adherence to a vaccination schedule following adult allogenic haematopoietic stem cell transplants in UK transplant centre. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S203-S204)
Greenfield D, Shanklin V & Snowden J (2015) Implementing International HCT Late Effects Screening Guidelines in Clinical Practice: Outcomes. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S210-S210)
Hamblin A, Greenfield D, Gilleece M, Salooja N, Kenyon M, Morris E, Glover N, Miller P, Braund H, Peniket A , Shaw B et al (2015) Provision of Long-term Monitoring and Late Effects Services Following Allogeneic HSCT in Adults: A British Society of Blood and Marrow Transplantation (BSBMT) Survey of UK NHS-Based Programmes. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S91-S92)
Thomas SJ, Fisher K, Brown S, Snowden JA, Danson S & Zeidler M (2014) Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling. Blood, Vol. 124(21) (pp 4577-4577)
Oliveira MC, Labopin M, Henes J, Moore J, Del Papa N, Stanciu R, Sakellari I, Schroers R, Scherer HU, Kyrcz-Krzemien S , Daikeler T et al (2014) Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?. Blood, Vol. 124(21) (pp 2517-2517)
Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Akay OM, Armbrecht G, Plesner T, Snowden JA , Nahi H et al (2014) EFFECTS OF SINGLE-AGENT BORTEZOMIB (BTZ) AS POST-TRANSPLANT CONSOLIDATION ON MULTIPLE MYELOMA (MM)-RELATED BONE DISEASE: FIRST RESULTS FROM A MULTICENTER, RANDOMIZED PHASE 2 STUDY. HAEMATOLOGICA, Vol. 99 (pp 362-362)
Parrish C, Morris TCM, Williams C, Cairns DA, Cavenagh J, Snowden JA, Ashcroft J, Cavet J, Hunter H, Bird JM , Chalmers A et al (2014) Stem cells harvested after bortezomib-based re-induction for multiple myeloma relapsing after autologous stem cell transplant (ASCT) and those stored from first induction yield equal outcomes: results from the BSBMT/UKMF Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 165 (pp 62-63)
Owen RG, DeTute DM, Ashcroft AJ, Cairns DA, Fletcher M, Williams C, Cavenagh JD, Snowden JA, Rawstron AC, Parrish C , Morris TC et al (2014) The utility of minimal residual disease (MRD) assessment in post-first relapse re-induction: results from the BSBMT/UKMF Myeloma X (intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 165 (pp 65-66)
Veys P, Danby R, Vora A, Slatter M, Wynn R, Lawson S, Steward C, Gibson B, Potter M, de la Fuente J , Shenton G et al (2014) UK EXPERIENCE OF UNRELATED CORD BLOOD TRANSPLANTATION IN PAEDIATRIC PATIENTS. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S359-S359)
Snowden J, Marjanovic Z, Badoglio M, Saccardi R, Farge D & Party EBMTADW (2014) EVOLUTION, TRENDS AND LONG TERM OUTCOMES IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN AUTOIMMUNE DISEASES (ADS): A RETROSPECTIVE STUDY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT 1996-2013. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S43-S43)
Snowden J, Danby R, Ruggeri A, Marks D, Hough R, Pagliuca A, Potter M, Russell N, Craddock C, Clark A , Miller P et al (2014) UK EXPERIENCE OF UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) IN ADULTS: A RETROSPECTIVE ANALYSIS ON BEHALF OF EUROCORD AND THE BRITISH SOCIETY OF BLOOD AND MARROW TRANSPLANTATION (BSBMT). BONE MARROW TRANSPLANTATION, Vol. 49 (pp S233-S234)
Parrish C, Morris T, Williams C, Cairns D, Cavenagh J, Snowden JA, Ashcroft J, Cavet J, Hunter H, Bird JM , Chalmers A et al (2014) STEM CELL HARVESTING AFTER RE-INDUCTION WITH A BORTEZOMIB-BASED REGIMEN FOR MULTIPLE MYELOMA RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANT IS FEASIBLE, SAFE AND EFFECTIVE: RESULTS FROM THE BSBMT/UKMF MYELOMA X (INTENSIVE) TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S73-S74)
Snowden J, Badoglio M, Farge D & Party EBMTADW (2014) UPDATE OF THE ACTIVITY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP). BONE MARROW TRANSPLANTATION, Vol. 49 (pp S95-S96)
Cook G, Williams C, Cairns DA, Chalmers A, Cavenagh J, Snowden J, Parrish C, Ashcroft J, Yong K, Cavet J , Hunter H et al (2014) SUPERIOR DURABILITY OF RESPONSE WHEN A SECOND AUTOLOGOUS STEM CELL TRANSPLANT CONSOLIDATES BORTEZOMIB-CONTAINING RE-INDUCTION THERAPY FOR RELAPSED MULTIPLE MYELOMA (MM): FINAL RESULTS FROM THE BSBMT/UKMF MYELOMA X (INTENSIVE) TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S72-S72)
Ashcroft J, De Tute RM, Cairns DA, Fletcher M, Owen RG, Williams C, Cavanagh JD, Snowden JA, Rawstron AC, Parrish C , Morris TCM et al (2014) MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT IN POST-FIRST RELAPSE RE-INDUCTION IS PREDICTIVE FOR TIME TO PROGRESSION (TTP): RESULTS FROM THE BSBMT/UKMF MULTIPLE MYELOMA (MM) X INTENSIVE TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S79-S80)
Browett K, Tridente A, Hall J, Sorour Y, Snowden J, Mills GH & Webber S (2013) Mortality predictors in patients with haematological malignancies admitted to critical care. BRITISH JOURNAL OF ANAESTHESIA, Vol. 110(5) (pp 862-863)
Cook G, Williams C, Szubert A, Yong K, Cavet J, Hunter H, Bird J, Bell S, O'Connor S, Cavenagh J , Snowden J et al (2013) A second autologous stem cell transplant induces superior response durability following bortezomib-containing re-induction therapy for relapsed multiple myeloma: results from the BSBMT/UKMF myeloma x (intensive) trial. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S17-S17)
Morris C, Williams C, Bell S, Fletcher M, Szubert A, Yong K, Covet J, Cavenagh J, Snowden J, Ashcroft J , Brown J et al (2013) BSBMT/UKMF myeloma X relapse (intensive) trial: barriers to recruitment and randomization. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S210-S211)
Douglas KW, Hayden P, Hunter H, Johnson P, Malladi R, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D , Robinson S et al (2013) Use of plerixafor to rescue absolute and predicted mobilization failures: a UK and Ireland consensus. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S112-S113)
Morris TCM, Williams C, Bell S, Flrtcher M, Szubert A, Yong K, Cavet J, Cavenagh J, Snowden J, Ashcroft J , Brown J et al (2013) BSBMT/UKMF Myeloma X Relapse (intensive) Trial - challenges in recruitment and randomisation. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 161 (pp 52-52)
Stradwick S, Freemantle N, Snowden J, Rodrigues F & Brereton N (2012) Comparative Effectiveness of Lenalidomide Plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison. BLOOD, Vol. 120(21)
Alix J, Blackburn D, Sokhi D, Dalley C, Jessop H, Sharrack B & Snowden J (2012) Pulse high-dose cyclophosphamide in malignant multiple sclerosis may result in successful functional recovery and stem cell mobilisation to enable safe delivery of AHSCT. BONE MARROW TRANSPLANTATION, Vol. 47 (pp S227-S228)
Hummel S, Snowden J, Nield A, McGoldrick R, Harrison S, Swanborough F, Davis J, Goddard Y, Ward S, Ezaydi Y , Morley N et al (2012) Predicting increases in bed capacity for haematopoietic stem cell transplantation or intensive chemotherapy through simulation modelling of ambulatory care. BONE MARROW TRANSPLANTATION, Vol. 47 (pp S278-S278)
Samuelson C, Ezaydi Y, Cachia E, Greenfield D, Ahmedzai S, O'Toole L & Snowden J (2012) A STUDY OF THE CARDIORESPIRATORY LATE EFFECTS IN PATIENTS WITH ADVANCED INTENSIVELY TREATED MULTIPLE MYELOMA. HAEMATOLOGICA, Vol. 97 (pp 623-623)
Craddock C, Jilani N, Siddique S, Vyas P, Goodyear O, Dennis M, Yin J, Russell N, Snowden J & Crawley C (2012) AZACITIDINE IS WELL TOLERATED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND ITS ADMINISTRATION IS ASSOCIATED WITH A REDUCED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE. HAEMATOLOGICA, Vol. 97 (pp 21-22)
Dharmagunawardena RT, Pearce RM, Lee J, Apperley JF, Littlewood T, Wilson KM, Orchard K, Jackson G, Snowden JA, Kirkland K , Cook G et al (2011) A RETROSPECTIVE MULTI-CENTRE STUDY OF THE EFFECTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON PULMONARY FUNCTION. THORAX, Vol. 66 (pp A62-A62)
Dennis M, Goodyear O, Loke J, Jilani N, Siddique S, Ryan G, Khanum R, Snowden J, Griffiths M, Russell NH , Yin J et al (2011) Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response. BLOOD, Vol. 118(21) (pp 152-152)
Marsh JCW, Pearce RM, Koh MB, Tang D, Lim Z, Pagliuca A, Mufti GJ, Snowden J, Vora AJ, Gibson B , Gilleece MH et al (2011) National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). BLOOD, Vol. 118(21) (pp 26-26)
Tailor IK, Walker R, Dalley CD, Vora AJ, Collins N & Snowden JA (2011) Umbilical cord blood transplantation (UCBT) in teenagers and adults: Sheffield experience 2005-2010. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 68-69)
Greenfield DM, Ezaydi Y, Cachia E & Snowden J (2011) Endocrine, bone and nutritional 'late effects' in patients with advanced stage multiple myeloma following HSCT and other intensive treatment. BONE MARROW TRANSPLANTATION, Vol. 46 (pp S186-S186)
Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze C-P , Wulffraat N et al (2011) Diagnosis of Lupus, age at HSCT and CD34+graft selection are the main risk factors for secondary autoimmune diseases occurring after HSCT for autoimmune diseases: a retrospective study of the EBMT Autoimmune Disease Working Party. BONE MARROW TRANSPLANTATION, Vol. 46 (pp S84-S85)
Daikeler T, Labopin M, di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze C-P , Wulffraat N et al (2010) Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. BLOOD, Vol. 116(21) (pp 959-960)
Martinez C, Canals C, Alessandrino EP, Karakasis D, Pulsoni A, Leone G, Trneny M, Snowden J, Apperley J, Milpied N , Bossi A et al (2010) RELAPSE OF HODGKIN'S LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): IDENTIFICATION OF PROGNOSTIC FACTORS PREDICTING OUTCOME. HAEMATOLOGICA, Vol. 95 (pp S26-S26)
Oo N, Jones DA, Snowden J & El-Ghariani K (2010) Autologous peripheral progenitor cell harvesting in haematology patients: One centre experience. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 149 (pp 67-67)
Cachia E, Eiser C, Beeken R, McAtamney K, Greenfield D, Ezaydi Y, Walmsley S, Ross RJ, Coleman R, Ahmedzai SH , Snowden J et al (2010) A study of pain, peripheral neuropathy and psychosocial late effects in patients with intensively treated advanced multiple myeloma. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S396-S396)
Cachia E, Greenfield D, Ezaydi Y, Baxter L, Ahmedzai SH, Eiser C, Coleman R, Ross R, Snowden J & Grp LE (2010) A study of the endocrine, metabolic and nutritional late effects in patients with advanced intensively treated multiple myeloma. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S396-S397)
Snowden JA (2010) CHOICE OF CONDITIONING REGIMEN. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S3-S3)
Nield A, Charley C, Dalley C, Davis J, Goddard Y, Salt M, Snowden J, Sprigens N & Ward S (2009) High-dose melphalan with stem cell rescue in the ambulatory care setting: the process to enable the concept to become a realistic treatment option. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S319-S319)
Fredrick L, Beeken R, Taylor N, Eiser C, Wright J, Snowden J & Dalley C (2009) Quality of life in adult survivors of blood and marrow transplantation correlates strongly with physical and psychological late effects of treatment: a mixed methods approach. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S180-S180)
Kuhl JS, Kohler W, Bandmann O, Buchholz S, Hemmati P, Snowden J, Sokolowski P, Stadler M, Terwey T & Arnold R (2009) Bone marrow transplantation in adult cerebral X-linked adrenoleukodystrophy: an update. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S182-S183)
Alfred A, Mahmood S, Jones DA, Hess D, Wright J, Snowden JA & Mijovic A (2009) High-dose G-CSF is safe and effective for mobilisation of haemopoietic cells for autologous stem cell transplantation with clinical utility in the majority of sub-optimal mobilisers. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S114-S115)
Craddock C, Tauro S, Buckley L, Kottaridis P, Thelouli E, Thomson K, Milligan D, Liakopoulou E, Snowden J, Marsh J , Hunter A et al (2008) PATIENT AND DONOR CHARACTERISTICS DETERMINE OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 93 (pp 354-354)
Craddock CF, Tauro S, Gregory JE, Buckley L, Ward J, Kottaridis P, Thelouli E, Thomson K, Milligan D, Das-Gupta E , Liakpopoulou E et al (2007) Factors predicting long term survival after reduced intensity allogeneic stem cell transplantation in acute myeloid leukemia. BLOOD, Vol. 110(11) (pp 103A-103A)
Sorour Y, Robinson K, Hurlstone P, Ei-Ghariani K, Lobo A & Snowden JA (2006) High-dose immune immunoablative therapy and autologous stem cell transplantation in severe resistant Crohn's disease: profound response for 18 months followed by treatable relapse. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S341-S341)
Alfred A, Throssell D, Ezaydi Y, Jones B, Reilly JT & Snowden JA (2006) Successful myeloablative allogeneic haemopoietic stem cell transplantation in a patient with end-stage renal failure on haemodialysis. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S350-S350)
Chantry AD, Snowden JA, Craddock C, Marks DM & Transplantat BSBM (2006) Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukaemia in second remission: a British Society of Bood and Marrow Transplantation Registry study. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S9-S10)
Feyler S, Rawstron A, Jackson G, Snowden J, Hawkins K & Johnson RJ (2005) Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.. BLOOD, Vol. 106(11) (pp 190A-190A)
Feyler S, Jackson G, Rawstron A, El-Sherbiny YM, Snowden JA & Johnson RJ (2003) Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.. BLOOD, Vol. 102(11) (pp 691A-691A)
Ponchel F, Papadaki H, Bingham S, Verburg R, Moore J, Protheroe A, McGonagle D, Snowden J, Van-Laar J, Markham AF , Emery P et al (2003) Il-7 and therapy-induced lymphopenia in RA. ANNALS OF THE RHEUMATIC DISEASES, Vol. 62 (pp 164-164)
Frost L, Wilson G, Goodeve A, Gerrard M, Snowden J, Peake I & Vora A (1999) Relapsing precursor B-ALL presenting as CD-10 positive isolated extramedullary lymphoma.. BLOOD, Vol. 94(10) (pp 219B-219B)
Kass-Iliyya L, Snowden JA, Thorpe A, Jessop H, Chantry AD, Sarrigiannis PG, Hadjivassiliou M & Sharrack B () Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. Journal of Neurology

Grants

NIHR Efficacy & Mechanistic Evaluation (EME), Health technology Assessment (HTA), Research for Patient Benefit (RfPB)and Biomedical Research Centre (BRC)
Accelerating Clinical Trials (ACT)/DIDACT Foundation, to support Sheffield Teaching Hospitals NHS Foundation Trust within the IMPACT and TAP Clinical Trials Networks.
Sheffield Hospitals Charity (SHC).
Blood Cancer UK (BCUK, formerly called Bloodwise/Leukaemia and Lymphoma Research/Leukaemia Research Fund).
Cancer Research UK (CRUK).
Myeloma UK Research Grant Programme.
Macmillan Cancer Support.
Health Foundation SHINE Award.
Healthcare Quality Improvement Partnership.
Kay Kendall Leukaemia Fund (KKLF).
Weston Park Hospital Cancer Appeal.
Arthritis Research Campaign (ARC).
National Institutes of Health (NIH)/National Cancer Institute (NCI) of USA.
National Health & Medical Research Council (NHMRC) of Australia.

Postgraduate awards

Health Service Journal/Nursing Times winner Best Cancer Care Team Award 2014 (with Prof Diana Greenfield for Late Effects Service).
Anthony Nolan Clinical Supporter of the Year Award 2016.
2019 NHS Parliamentary Awards, winner of ‘The Future NHS Award’ to Professor Basil Sharrack and Professor John Snowden.
2020 Clinical Research Forum (USA) Top Ten Research Achievement Awards, with Richard Burt.

Teaching activities

I have been actively involved in teaching and lecturing in undergraduate medicine locally, nationally and internationally.
Examiner for BMedSci students, University of Sheffield.
Clinical co-supervisor and personal tutor for doctorate (PhD and MD) students at University of Sheffield and UCL.
Module Co-Lead for MSc(Res) in Translational Oncology (Cancer Diagnosis and Treatment), University of Sheffield.
Examiner for MD/PhDs at The University of Sheffield, and external at University of Birmingham, Newcastle University, and University of Oxford.
Educational supervision of postgraduate specialist training of numerous specialist trainees through the Membership of Royal College of Physicians and Pathologists examinations.
Examiner for the Royal College of Pathologists.

Professional activities and memberships

Sheffield Teaching Hospitals NHS Foundation Trust (STHFT)

Director of Blood and Marrow Transplant & Cellular Therapy Programme (2002-25).
Lead Clinician for Haemato-Oncology, STHFT Cancer Services Steering Group (2005-07) and Cancer Executive (2002-05).
Lead Clinician in Haematology Late Effects Service (2008-25).

The University of Sheffield (TUoS) and University College London (UCL)

Honorary Professor, Department of Oncology & Metabolism, now Division of Medicine, TUoS (from November 2013).
Honorary Reader, Department of Oncology, TUoS (2010-2013).
Honorary Clinical Professor, Department of Haematology, The Cancer Institute, UCL (2016-25).

Regional NHS Cancer Roles

Lead Clinician, Network Site Specific Group (NSSG) for Haemato-Oncology (2007-10), and acting chair/vice-chair of NSSG (2014-15).
Chair, NSSG Working Party for the Haemato-Oncology Diagnostic Service (2005-07).
Co-Lead Clinician for Haematology-Oncology in the NHS England Genomic Laboratory Hub (GLH) for North-East & Yorkshire (NEY) region (2019-2025).

National roles and responsibilities

National Cancer Research Institute (NCRI) Clinical Studies Group (CSG) in Haematological Oncology: Member by appointment (2008-17) and Chair of the Supportive Care, Transfusion & Late Effects Working Party (2015-17), Member of Aplastic Anaemia Working Group (2017-19).
National Confidential Enquiry into Patient Outcomes and Death (NCEPOD), Member of Expert Working Group for Systemic Anti-Cancer Chemotherapy, from 2006 until publication of report ‘Systemic Anti-Cancer Therapy: For better, for worse?’ in 2008.
UK Myeloma Forum Executive, Elected Member, 2009-15.
Chair (2016-20), and Member of NHS England Clinical Reference Group (CRG) for National Specialised Commissioning of BMT Services (2011-2024).
Chair of the National Clinical CAR-T Panel (NCCP) for acute lymphoblastic leukaemia (2018-19).
BSBMTCT Executive Committee Member (elected) 2012-2015, Secretary (elected) 2015-18, President-elect (elected) 2019-20, and then President, 2021-22, Past President, 2023-24.
Member, UKNEQAS Leucocyte Immunophenotyping Steering Committee 2014-present.
Co-Lead Clinician for Haemato-Oncology of the North East & Yorkshire region Genomic Laboratory Hub (GLH) 2019-25.
NICE and other NHS related organisations
- Expert clinical member of NICE Guideline Development Group in Myeloma (NG35), 2014-15. https://www.nice.org.uk/guidance/ng35
- Clinical Lead, NICE IOG for Haematological Cancers NG47, 2015-16. https://www.nice.org.uk/guidance/ng47
- Clinical Co-Lead for COVID-19 rapid NICE Guidance in HSCT (NG164), 2020-21. https://www.nice.org.uk/guidance/ng164
- Healthcare Improvement Scotland: Scottish Health Technology Guidance (SHTG) Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding to high efficacy disease modifying therapies (as expert advisor) Published date: October 2019 http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/topics_assessed/shtg_07-19.aspx
- Health Technology Wales: Expert Consultation: Autologous haematopoietic stem cell transplantation to treat people with previously treated relapsing remitting multiple sclerosis (EAR019) (as expert advisor). Publication date July 2020 https://www.healthtechnology.wales/reports-guidance/autologous-haematopoietic-stem-cell-transplantation/
- UK Stem Cell Strategic Forum ‘A ten-year vision for stem cell transplantation’. Publication date July 2022. As President of BSBMTCT, I was an integral member of the UK Stem Cell Strategic Forum report, sponsored by NHSBT and supported by Anthony Nolan. https://www.nhsbt.nhs.uk/who-we-are/performance-and-strategy/stem-cell-and-advanced-cellular-therapy-strategy/

International roles and responsibilities

Secretary to the European Society for Blood and Marrow Transplantation EBMT (2020-24)
Chair of the EBMT Autoimmune Diseases Working Party (2016-20), having been Secretary (2010-16).
EBMT JACIE Committee, as Chair (2015-20) and Medical Director (2012-16).
JACIE Committee Chair (from April 2015-July 2020) & JACIE Medical Director (2012-16).
Worldwide Network for Blood and Marrow Transplantation (WBMT) Executive Member (2015-24).

Other Working Parties and Guidelines Groups

EBMT Transplant Complications Working Party (TCWP) and Severe Aplastic Anaemia Working Party (SAAWP).
BSH/UKMF Myeloma Guidelines Group (Lead in Supportive Care and Long Term Monitoring Guidelines).
BSH Aplastic Anaemia Guidelines Group 2014-present.

Scientific Organising Committees, Scientific Journal Editorship and Peer Review Work

Scientific/organising committee membership e.g. many Annual EBMT Congresses and Educational Events & and BSBMTCT educational and scientific days.
Associate Editor, Current Research in Translational Medicine (2013-present), Associate Editor Frontiers in Immunology specialty section ‘Alloimmunity and Transplantation’ (2021-).
Editorial Board Member, Blood Advances (2021-present), International Journal of Laboratory Haematology (2006-2021).
Guest Editorships, Frontiers in Immunology Special Edition on ‘Biomarkers in Graft versus Host Disease’ 2019-20, Clinical Medicine (Journal of the Royal College of Physicians of London) for Haematology CME 2018, Current Opinion in Supportive and Palliative Care 2017 special edition on Haematology.
Peer reviewer for scientific journals, conference abstracts and international, national and local grant applications.
Peer reviewer for University Professorship promotions.

Clinical Trials Networks and Committees

Principal Investigator for Clinical Trials Networks (CTNs):
- Cure Leukaemia Therapy Acceleration Programme (TAP, funded 2020-22).
- DIDACT Foundation IMPACT BMT CTN (funded 2023-26).
Membership of Trial Management Groups (TMG, Data Monitoring and Ethics Committee (DMEC) and Trial Steering Groups (TSG) for many clinical trials.

Media and related work

Radio and TV as an expert opinion on haemato-oncology and stem cell transplantation, including collaborative work on Haematopoietic Stem Cell Transplantation in Multiple Sclerosis was featured increasingly in media leading to a BBC Panorama documentary ‘Can You Stop My MS?’ aired in 2016 to estimated 2.4 million live, with subsequent broadcast interview coverage and other on-line coverage reaching an estimated 180 million worldwide.
Also featured in many national newspapers and their on-line versions.

Examples of invited lectures, chairing and organising committees for last 10 years

2016

Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Berlin, January 2016.
Invited Speaker, Autoimmune Diseases Meeting, Porto, Portugal, January 2016.
Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Meeting, Valencia, April 2016.
Invited Speaker, XXXVI World Congress of the International Society of Hematology hosted by the British Society for Haematology, Glasgow, April 2016.
Invited Speaker, EBMT Highlights, Jeddah, Saudi Arabia, May 2016.
Invited Speaker, Uppsala University, Sweden, May 2016.
Invited Speaker, Department of Neurology, Oxford University, June 2016.
Invited Speaker, Myeloma UK Symposium, Birmingham, September 2016.
Organiser, Invited speaker, BSBMT Annual Educational Meeting, London, November 2016.
Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases and Severe Aplastic Anaemia Working Parties’, Paris, November 2016.
Organiser, Invited speaker, ‘Late Effects in Cancer Survivors’, Royal College of Physicians of London, November 2016.
Invited Speaker, Autoimmunity and Immunodeficiency Diseases Conference, Moscow, Russia, December 2016.

2017

Invited speaker and session chair, Tandem Meeting of the American Society for Blood and Marrow Transplantation (ASBMT) and Centre for International Bone Marrow Transplant Research (CIBMTR), Orlando, FL, USA, February 2017.
Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Marseille, March 2017.
Organiser, Invited Speaker, NCRI Haemato-oncology Annual Trials Day, May 2017.
Invited Speaker, ‘Inflammation, breaking down Silos’, Oxford University, June 2017.
Invited Speaker, University of Jordan, October 2017.
Organiser, Invited speaker, BSBMT Annual Educational Meeting, London, November 2017.
Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases and Inborn Errors Working Parties’, Newcastle, November 2017.

2018

Invited Speaker, Annual ECCO Congress, Vienna, February 2018.
Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Lisbon, March 2018.
Invited speaker, BSBMT Annual Scientific Meeting, London, May 2018.
Invited Speaker, EBMT Highlights, Riyadh, Saudi Arabia, May 2018.
Invited Speaker, EBMT Highlights, Delhi, India, May 2018.
Organiser, Invited speaker, EBMT International Training Course in BMT, September, 2018.
Organiser, Invited speaker/chair, BSBMT Annual Educational Meeting, London, October 2018.
Invited Speaker, UKE Hamburg-Eppendorf, Germany, October 2018.
Invited Speaker, Myelin Meeting, Leipzig, Germany, October 2018.
Invited speaker, Royal College of Physicians, London, October 2018.
Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases and Severe Aplastic Anaemia Working Parties’, Florence, November 2018.

2019

Invited speaker, Royal Society of Medicine, London, March 2019.
Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Frankfurt, March 2019.
Invited speaker, British Society for Cell and Gene Therapy (BSCGT) Annual Meeting, Sheffield, UK, June 2019.
Invited speaker, 61st National Congress of the Spanish Hematology and Hemotherapy Society and 35th National Congress of the Spanish Society of Thrombosis and Hemostasis, Valencia, Spain, October 2019.
Invited speaker, COSTEM (Controversies in Stem Cell Transplantation) Meeting, Berlin, Germany, October 19-21, 2019.
Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Berlin, Germany, October 31-November 1, 2019.
Invited speaker, international conference “Stem cell transplantation for treatment of autoimmune diseases: sharing the experience”, Moscow, November, 2019.
Invited speaker, organiser, national conference of the Intercollegiate Committee on Haematology “Updates, Controversies, Uncertainties”, Royal College of Pathologists, London, December 17, 2019.

2020

Invited speaker 4th French International Symposium on CAR T Cells, Faculty of Medicine and Lille University Hospital, Lille, France, January 2020.
Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Madrid, re-scheduled as virtual meeting to August 31-September 2, 2020.
Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Virtual Conference, September 24-25, 2020.

2021

Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT ‘Virtual’ Congress, March 14-17 2021.
Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Virtual Conference, September 23-24, 2021.
Invited speaker and session chair, ‘EBMT Covid-19 Summit’, Virtual Conference, June 29 – July 1, 2021.
Invited speaker (virtual), Departments of Haematology and Neurology, Leeds Teaching Hospitals, September 21, 2021.
Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Virtual Conference, September 23-24, 2021.
Invited speaker, UK Primary Immunodeficiency Network (UKPIN) Meeting, Sheffield, November 2, 2021.

2022

Invited speaker MS Academy - Live Webinar (with Prof Basil Sharrack) ‘UK stem cell transplantation in MS (the StarMS trial), January 27, 2022.
Invited online lecture to Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, February 9, 2022.
Invited speaker (online) University College Dublin Centre for Arthritis Research Seminar, February 18, 2022.
Organiser, Invited Speaker, Sessional Chair (online), 9^th Annual ECTRIMS Focused Workshop on Autologous haematopoietic stem cell transplantation for treatment of MS and related diseases, March 10-11, 2022.
Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT ‘Virtual’ Congress, March 19-23, 2022.
Invited Speaker, Northern Connections MS Meeting, Edinburgh, The Royal College of Physicians of Edinburgh, June 10, 2022.
Invited speaker, 30th Congress of the Polish Society of Haematology and Transfusion Medicine, September 8-10, 2022.
Invited speaker, MS At the Limits Meeting, Edinburgh, Royal College of Physicians of London, September 19, 2022.
Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Royal College of Pathologists, London, September 24-25, 2022.
Organiser, North East & Yorkshire Genomic Medicine Service Haemato-Oncology Symposium, October 10, 2022.
Organiser, Chair, BSBMTCT Annual Educational Meeting, London, November 1, 2022

2023

Organiser, Invited Speaker, Sessional Chair, The 3rd International Symposium on Stem Cell Treatment in Multiple Sclerosis – SITraN, Sheffield, 20 January 2023
Organiser, Invited Speaker, Sessional Chair, Annual EBMT Congress, Paris, April 23-26, 2023.
Invited virtual lecture to New York Medical College, Westchester Medical Center, Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, April 10, 2023.
Invited virtual lecture at the Florey Institute Symposium, The University of Sheffield, 27 April, 2023.
Invited online lecture to 1st Jordanian International Convention of Transfusion Medicine and Hematopoietic Stem Cells, May 6, 2023.
Invited Speaker, EBMT Midterm Meeting on Immunedysregulatory, Autoinflammatory and Autoimmune Diseases, Brescia, Italy, June 22-24, 2023.

2024

Sessional Chair, Annual EBMT CAR-T Meeting, Valencia, Spain, February 15-17, 2024.
Organiser, Invited Speaker, Sessional Chair, Annual EBMT Congress, Glasgow, UK, April 14-17, 2024.
Invited Speaker, British Society for Haematology (BSH) Annual Scientific Meeting, Liverpool, UK, April 27-30, 2024.
Invited speaker and session chair, EBMT Joint Educational Meeting of Cellular Therapy & Immunobiology Working Party and Autoimmune Diseases Working Party, Milan, Italy, October 9-11, 2024.